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ABSTRACT 
 
Chenchen Wang: Pulmonary Delivery of Isoxyl Particles to Treat Mycobacterium 
tuberculosis 
(Under of the direction of Anthony J Hickey, Ph.D.) 
 
Isoxyl is an effective drug to treat multi-drug resistant tuberculosis but its use was 
impaired by failure in clinical trials. Due to absence of reliable quantitive analytical methods 
at that time, the reasons for these poor in-vivo outcomes were not determined. In the present 
work, an HPLC method was developed and validated for determination of isoxyl 
concentrations in plasma. Pilot studies showed that therapeutic plasma concentrations were 
not achieved after oral administration of isoxyl to guinea pigs. Pulmonary delivery may 
rescue the drug by targeting isoxyl particles to macrophages, the host cells of mycobacteria. 
Isoxyl particles with various size and shape were prepared by antisolvent precipitation. 
Subsequent spray drying produced microparticles < 5 µm suitable for lung delivery. Isoxyl > 
5 µg/ml, independent of particle form, seemed effective in killing intracellular mycobacteria 
without cytotoxicity. This work is the basis for reviving drugs with undesired physico-
chemical properties to treat lung infection. 
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Chapter 1 
Background and Specific Aims 
 2
1.1 INTRODUCTION 
1.1.1 Tuberculosis 
Tuberculosis (TB) is the leading cause of death by a single infectious micro-organism. 
One third of the world’s population has been infected by TB, with 9.27 million new cases 
and 1.8 million deaths in 2007 according to World Health Organization (WHO) report.1 The 
availability of the vaccine Bacillus Calmette-Guerin (BCG) and curative chemotherapies 
were responsible for the general decrease in tuberculosis mortality in the past century. 
Nevertheless, the frequency of occurrence of new cases began to increase in the mid-1980s. 
Two main factors contributed to the resurgence of TB, the occurrence of immunosuppressive 
diseases, such as HIV infections, and the emergence of multi-drug resistant (MDR) strains, 
which are resistant to isoniazid and rifampicin, the two first line anti-tuberculosis drugs.2-5 
Mycobacterium tuberculosis is mainly transmitted by airborne droplet aerosols 
containing 1 to 3 tubercle bacilli. After the bacilli are inhaled and deposited into the alveoli, 
they are phagocytized to endosomes of alveolar macrophages. In healthy immunocompetent 
humans, this induces cell-mediated immunity (CMI) and formation of granulomas. Early 
stage granulomas consist of CD4+, CD8+ and other T cells. Late stage granulomas form a 
fibrotic wall and lymphoid follicular structures to contain the spread of bacilli by depriving 
them of oxygen and nutrients. Successful CMI forms granulomas containing non-viable 
bacilli which can persist for decades. 5 However, in the weakened immune system, these 
bacilli are released from the macrophages. These bacilli are ingested by surrounding poorly 
activated immunologically compromised monocytes or macrophages and then multiply 
intracellularly. The development of tissue-damaging delayed-type hypersensitivity (DTH) 
can kill these bacilli-laden cells, but also expand the caseous necrotic center and cause 
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damage to lung tissue. This leads to clinical manifestations of the disease. With the progress 
of the disease, the caseum is liquefied and, thus, provides an excellent intercellular growth 
environment for the bacilli. The large numbers of intercellular bacilli result in cavity 
formation as well as resistance even in response to a strong CMI. 5-7 Though the clinical 
manifestations can occur in almost any organ as bacilli migration via lymphatics to the 
systemic circulation, about 85% TB infection occurs in lungs in humans without human 
immunodeficiency virus (HIV) infection. The HIV infection can increase the occurrence of 
extra-pulmonary infections to 68%.8  
 
1.1.2 Anti-tuberculosis Drugs and Isoxyl 
The successful modern chemotherapy of TB started in 1944 when streptomycin (SM) 
was administered to the first patient.9 The subsequent use of the first-line antituberculosis 
drugs, such as isoniazid (INH), rifampicin, ethambutol, and pyrazinamide (PZA), lead to a 
steep decline in TB incidence. The chemotherapy of TB disease requires combination of 3 to 
4 drugs over an extended period of 6 months to 2 years. The lengthy therapy results in patient 
noncompliance, and contributes to poor therapeutic outcomes and emergence of MDR 
strains.10  This requires the  use of second-line drugs such as capreomycin, ethionamide 
(ETH), cycloserine and kanamycin which are more toxic and cannot be administered 
frequently.11 Therefore, the absence of novel effective TB therapy remains a significant 
public health threat worldwide due to rapid development of multi-drug resistant strains 
(MDR) and extremely-drug resistance strains (XDR). Development of potent 
chemotherapeutic alternatives is crucial to preventing future epidemics of this insidious form 
of the disease. 
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Figure 1. The chemical structures of isoxyl (A) and N,N'-bis[4-(1,1-dimethylethyl)phenyl]-
thiourea (B). 
 
Isoxyl (ISO, thiocarlide, 4,4’-diisoamythio-carbanilide) [Figure 1A] is an second-line 
drug synthesized in 1953 by Buu-Hoi and Xuong 12, and began to be used clinically to treat 
tuberculosis in the 1960s. Two mechanisms of action of isoxyl have been proposed: 1) It 
inhibits short-chain fatty acid biosynthesis distinct from the mechanisms of INH and ETH; 
and 2) Similar to INH and ETH, it inhibits the biosynthesis of mycolic acid which is 
hallmark of mycobacterial cell wall.10, 13 Phetsuksiri et al.14 reported that the                        
antituberculosis effect of isoxyl is primarily due to inhibition of oleic acid biosynthesis other 
than mycolic acid biosynthesis. Isoxyl inhibits the activities of desA3, a fatty acid desaturase 
in M. tuberculosis converting stearoyl-CoA to oleic acid, a monounsaturated fatty acid that is 
necessary for membrane fluidity to form a lipid bilayer at physiological temperature.15 Some 
recent studies proposed that isoxyl is a prodrug that is converted to transient reactive 
intermediate(s) by the flavin adenine dinucleotide (FAD)-dependent monooxygenase EthA 
located in M. tuberculosis. EthA can activate isoxyl and other thiocarbamide-containing 
drugs such as ETH and thioacetazone (TAC) to bind to their distinct cellular targets. This 
explains some cross-resistance between isoxyl, ETH and TAC.16, 17  
The unique mechanism of action makes isoxyl a potentially efficient antituberculosis 
drug for treatment of the MDR strains in monotherapy or in a combined regimen. In-vitro 
studies showed that isoxyl have strong antimycobacterial activity with MIC (minimum 
N
S
N
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A B 
N
S
N
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inhibitory concentration) of 2.5 µg/ml for Mycobacterium tuberculosis H37Rv, MIC of 0.5 
µg/ml for Mycobacterium bovis BCG, MIC of 2.0 µg/ml for both Mycobacterium avium and 
Mycobacterium aurum A+, and MIC of 1-10 µg/ml for various clinical isolates of strains 
resistant to rifampicin and INH.13 Clinical studies conducted decades ago, without regulatory 
controls, revealed that isoxyl was more effective than PZA, thiosemicarbazon (TSC), 
viomycin (VM) and p-aminosalicylic acid (PAS), equivalent to ethionamide and kanamycin, 
and inferior to INH, SM and cycloserine. It has been reported that isoxyl is effective in 
treating tuberculosis strains resistant to INH, PAS, ETH, and SM, but not sensitive to the 
TSC-resistant strains. Isoxyl in combination with SM or ETH showed synergistic effects.18, 19 
In particular, isoxyl can maintain a long-term therapy level in combination therapy. Addition 
of isoxyl to capreomycin, rifampicin, and ethambutol dramatically increased the survival rate 
of rabbits infected with M. bovis 20[Figure 2]. It was reported that oral administration of 
isoxyl leaded to no toxicity to liver, kidney and hemopoietic systems but marginal gastro-
intestinal symptoms in human. 18, 21-23 Therefore, isoxyl may be a good substitute for the 
other second-line drugs which are not well tolerated. 
However, the effectiveness of isoxyl has been questioned due to failure in some clinical 
trials.14, 24 The most plausible explanation for these failures is that isoxyl is almost 
completely insoluble in water (solubility calculated by advanced chemistry development 
(ACD/labs) software V8.14 for Solaris: 1.3×10-6 mol/L at 25°C) and, consequently, exhibits 
poor dissolution and bioavailability when it is delivered exclusively by the oral route. Efforts 
to improve the oral absorption of isoxyl, including use of micropowders or suspension in 
olive oil, resulted in no improvement of isoxyl absorption and the majority of the 
administered dose was still eliminated intact via the feces.12, 25 Development of a more 
 6
convenient and effective delivery method is a prerequisite for successful employment of 
isoxyl for TB chemotherapy. 
 
Figure 2. Single or combination therapies increased survival rate of rabbits infected with 
Mycobateria bovis.20 
 
1.1.3 Pulmonary Delivery 
Pulmonary tuberculosis is a major manifestation of TB implicated in morbidity and 
systemic dissemination. However, when antitubercular drugs are administered orally, drug 
concentrations in plasma and the lungs are well below the suggested therapeutic range in 
some patients.26-28 Additionally, only a small fraction of an oral dose of drug delivered to the 
lungs can access granulomas, tubercles or lesions which have very poor blood supply.29 This 
suboptimal drug concentration contributes to prolonged duration of treatment, relapse and 
development of MDR strains. 
The previous poor therapeutic outcomes of isoxyl delivered orally may be caused by 
insufficient and highly variable drug concentrations in the lungs. In contrast, inhalation of 
isoxyl may achieve higher lung tissue to plasma concentration ratio. Maximizing local 
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concentration may increase drug efficacy and shorten duration of treatment against 
pulmonary tuberculosis. Ideally, inhalation therapy will result in higher concentrations of 
isoxyl in the lungs while maintaining therapeutically effective plasma concentration to treat 
the systemic infection. However, in some cases, the dose given by pulmonary route may not 
allow sufficiently high drug levels in systemic circulation. This can be overcome by 
supplementing with oral therapy using conventional drugs. Compared to parenteral delivery, 
oral and pulmonary administrations are non-invasive and can be achieved by self-
administration. This is important for treatment of TB, because TB is a disease most 
commonly occurring in the developing world where needles, syringes, water for injection and 
cold storage conditions may be hard to obtain and the duration of anti-tuberculosis therapy is 
long.   
Since most tubercle bacilli initially reside in the macrophages/monocytes in the lungs, 
the main targets of isoxyl should be these infected cells. Pulmonary delivery may facilitate 
efficient dosing of isoxyl to the targets by two main possible pathways: 1) isoxyl particles 
may dissolve in lung surface lining fluid and the resulting free drug molecules can either 
diffuse through the thin alveolar epithelium (0.1 to 0.5 µm) via interstitial fluid to the 
surrounding infected tissue, or pass all the way through the epithelium, interstitium, 
basement membrane, and vascular endothelium to enter the bloodstream, from which they 
are then redistributed to the infected tissue; and 2) Isoxyl particles can be taken up by 
macrophages/monocytes which may be recruited to granulomas. Targeting to alveolar 
macrophages is known to enhance efficacy due to specific drug action at the main site of 
infection30 and through macrophage activation31. However, it is still not clear which of the 
two pathways is more efficient for action of anti-tuberculosis drugs.  
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The unique features of the lungs offer distinct advantages for pulmonary delivery of 
drugs, such as isoxyl, that are believed to have low bioavailability following oral 
administration: 1) Drugs can achieve higher lung tissue to plasma concentration ratio;32 2) 
hydrophobic drugs have higher solubility and more rapid dissolution rates in the surface 
lining fluid containing large quantities of lung surfactants;33 3) the lungs are thought to have 
fewer metabolizing enzymes and efflux transporters in contrast to the gastro-intestinal tract 
where orally administered drugs undergo first-pass effects of the gut and liver34; and 4) more 
importantly, drug particles delivered to the lungs have been shown to target to 
macrophages/monocytes, the host cells for MTB. Theoretically, the respiratory airways in the 
periphery of the lungs are probably the best place for deposition of isoxyl. These areas are 
patrolled by most abundant alveolar macrophages with an average of 50 to 100 per 
alveolus.35 Mucociliary drug clearance from the deep lung is considerable slower than that 
from the conducting airways.34 Deposition in the periphery of the lungs to target macrophage 
must be balanced against drug dissolution and absorption. The latter may be rapid since there 
is enormous internal surface area (about 100 m2)36, 37, thin alveolar epithelium and 
tremendous vascular system of the distal lung enable efficient transport of isoxyl to 
interstitium and bloodstream. An optimal balance between phagocytosis and dissolution 
would be beneficial for TB therapy. TB is a systemic infection, which might benefit from 
higher concentrations of isoxyl in the lungs while requiring maintenance of therapeutically 
effective plasma concentrations.   
Deposition of particles in the lungs is mainly determined by five mechanisms, inertial 
impaction, sedimentation, diffusion, interception and electrostatic deposition. The first three 
are most important for most therapeutic particles because electrostatic force is only important 
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in highly charged particles and interception mostly influences long fibers. Inertial impaction 
is caused by inability of particles to adjust to new directions of airflow before encountering 
the airway surface. At the average inspiratory flow rate, impaction mostly affects the larger 
particles (aerodynamic diameter da >1 µm). In general, particles with aerodynamic diameter 
of about 1 to 3 µm deposit in the alveolar region if they are slowly and deeply inhaled.38 For 
these particles, diffusion (significant for particles da <1 µm) is negligible. Therefore, inertial 
impaction and gravitational settling are the most important factors for particles depositing in 
the lower airways. These phenomena occur as a result of aerodynamic properties. The 
aerodynamic diameter of spherical particles is related to the volume (geometric) diameter 
according to Stokes’ law: 
                                                 η
ρ
ηχ
ρ
1818
2
0
2
cacep
TS
gCdgCdV ==                                          [1] 
Where ρp and ρ0 are the particle density and the unit particle density (1000 kg⋅m-3) 
respectively, χ is a shape factor, η is the viscosity of atmosphere, de is the equivalent volume 
diameter that is the diameter of a sphere having the same volume as that of the irregular 
particle, da is the aerodynamic diameter which is the diameter of a particle of the unit density 
having the same settling velocity as that of the irregular particle, and Cc is a slip correction 
factor necessary for particles with a diameter of less than 1 µm.  
 
1.1.4 Microparticles and Nanoparticles 
Particle size and distribution are the most critical factors determining the delivery 
efficiency of drug to the lungs. Dry powder inhalers (DPI) can be employed to deliver the 
microparticles or nanoparticle aggregates with aerodynamic diameter between 1 to 5 µm. 
However, individual isoxyl nanoparticles may be too small to be retained in the lungs, which 
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should be a rare occurrence due to particle aggregation. Primary sizes of nanoparticles may 
be achieved by nebulizing nanosuspension to the lungs. Delivery of nanosuspensions may be 
an attractive means because they may have more homogenous distribution in carrier droplets 
and based on previous reports produce higher respirable fraction relative to microparticle 
suspensions.39-41 
Success of TB therapy is dependent largely on effectiveness of anti-tuberculosis drugs in 
eliminating mycobacteria residing in phagosomes of alveolar macrophages. It has been 
reported that particles with diameters of 500 nm to 3µm are phagocytized efficiently when 
these particles encounter alveolar macrophages.42-44 Phagocytosis of hydrophobic 
nanoparticles decreases with decreasing size.45  Cellular uptake of drug particles results in 
containment of both drug and bacilli in a cell. This might improve drug efficacy and shorten 
duration of treatment.39, 46 Moreover, granulomas are formed by recruiting 
macrophages/monocytes, it is postulated that accumulation of drug in macrophages will 
facilitate transportation of drug to granulomas.47 This may lead to a conclusion that 
microparticles, or aggregated nanoparticle, might be more effective in drug delivery than 
separated nanoparticles due to higher macrophage phagocytosis. However, it deserves further 
investigation. For example, if nanoparticle aggregates are broken down to discrete individual 
particles or microparticles dissolve quickly outside the macrophages, they may escape 
phagocytosis. Also, the relation of macrophage phagocytosis and drug efficacy remains 
controversial. Many studies have showed that accumulation of drugs in phagosomes 
simultaneously enhanced killing of intracellular mycobacteria48, 49, while some studies did 
not 3. This might be explained by isolation of bacilli and drugs in different intracellular 
phagosomes.3 If drugs were trapped in the isolated phagosomes, the effectiveness of drug 
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against intracellular mycobacteria would be reduced. Therefore, the correlation between 
macrophage targeting and drug efficacy may be drug-dependent and should be studied on a 
case by case base. 
Besides achieving sufficient drug concentration in macrophages in the lungs, it is also 
desired to maintain therapeutic drug concentration systemically to teat TB infection. The 
level of systemic distribution of drug from the lungs is determined by the balance between 
phagocytosis and dissolution. Particle size is also an important factor for rate of dissolution. 
The small particle size increases the surface area and intrinsic solubility of the drug that 
result in a relatively rapid dissolution rate 50. This is described by the following equations 2 
and 3: 
                                        
RTr
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s −=  (Noyes & Whitney equation)                           [3] 
Here, Cs/Co is the saturation ratio that is the solubility of a small particle with radius r over 
the solubility of a very large crystalline particle, γ is the surface tension of the particles, Vm is 
the molar volume, R is the gas constant, T is the absolute temperature, dC/dt is the 
dissolution rate, D is the diffusion coefficient of the drug in solution, As is the total surface 
area of the drug, h is the thickness of the diffusion layer, V is the volume of solution, and C is 
the concentration of the drug in the solution at time t. Theoretically, nanoparticles exhibit 
more rapid dissolution rate in alveolar lining fluid and, consequently, a faster absorption rate 
of the drug through pulmonary epithelium than microparticles. Also, it was reported that 
particles smaller than 500 nm in diameter were phagocytized by alveolar macrophages to a 
smaller extent than 1-5 µm microparticles. 43, 44, 51 Dendritic cells may take up these 
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nanoparticles,52 but the kinetics of this phenomenon will be influenced by rapid dissolution 
of the particles in alveolar lining fluid. Therefore, a portion of nanoparticles may escape from 
monocyte uptake which leads to an increase in systemic drug exposure. However, all of these 
may not be true due to formation of nanoparticle aggregates which reduce the surface area to 
the level comparable to microparticles. Moreover, if the solubility of isoxyl in the lung lining 
fluid is extremely low, dissolution of drug from the nanoparticles may not be fast enough to 
avoid uptake by macrophages or epithelial cells.  In this scenario, the difference of 
nanoparticles and microparticles may not be obvious. In addition to potential difference in 
dissolution and absorption, for ultrafine particles (< 100 nm), they may be able to be 
translocated intact to the blood circulation after inhalation exposure53-57. Uptake of 
nanoparticle by pulmonary epithelial cells will increase with decreasing size.58 However, 
there are many conflicting results regarding epithelial cell transport. The amount of drug 
particles translocated by this mechanism is much smaller than macrophage uptake and 
molecular drug diffusion. Nemmar et al. 53 reported that significant amount (25-30%) of 
99mTc-albumin nanocolloid particles (<80 nm) will be translocated from the lungs to the 
systemic circulation rapidly. But Nicolas et al. 59 revealed that 95.7% of the same particles in 
the lungs 6 hours after inhalation. Particle properties, including size, surface area, charge, 
number and coating, will influence uptake by macrophages and pulmonary epithelial cells. 
Therefore, many in-vitro studies including dissolution, cellular uptake of particles by 
macrophages and epithelial cells are necessary to predict in-vivo disposition of the drug. 
In this study, particles of various size distributions were produced by changing 
processing conditions. The potentially different disposition of isoxyl nanoparticles and 
microparticles may result in change in magnitudes or mechanisms of cytotoxicity toward 
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macrophages and efficacy of the drug in treating the infected cells in-vitro. One purpose of 
the study is to evaluate the effect of isoxyl characteristics on drug cytotoxicity and efficacy. 
The study will illustrate mechanisms of isoxyl targeting at a cellular level, which may be 
beneficial for resurrecting the old clinically unproven drug or for designing more novel 
potent anti-tuberculosis drugs13, 60. 
 
1.1.5 Cell Culture and Animal Models 
Targeting to phagocytic cells, host cells of mycobacteria, is believed to increase 
antituberculosis drug efficacy. To study the correlation of macrophage targeting and anti-
tuberculosis effectiveness of isoxyl, selection of an appropriate macrophage model is a 
prerequisite.  Several primary cell models or continuous cell lines have been used to mimic 
in-vivo macrophages that associate with mycobacteria. Human primary 
monocytes/macrophages or primary alveolar macrophages were isolated from the blood or 
lavage of healthy volunteers.61, 62 63These cells are the best representatives to in-vivo situation, 
but their application is scarce due to availability of the resources, heterogeneity of the cells 
and cost consideration. Murine primary alveolar macrophage model are an alternative cell 
model. These cell are cheaper to obtain and easier to manipulate genetically. However, 
species differences are always a concern. The human and the mouse have different degrees of 
susceptibility to mycobacteria, so the killing mechanism of murine macrophages can be 
different from that of human macrophages.64 The same potential problem may arise in 
murine macrophage cell lines such as J774 and NR8383. Human macrophage-like cell line is 
a good model. Human macrophage-like cells show absence of donor variability, easily 
proliferate, and are cost-effective. The human acute monocytic leukemia cell line (THP-1) 
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has been widely used. 65-68 These cells can be differentiated by Phorbol Myristrate Acetate 
(PMA) to macrophage-like cells. Stokes at el. 69 reported that the differentiated THP-1 cells 
associate with mycobacteria in the similar way to human monocyte-derived macrophages 
(MDMs) from blood of healthy adult volunteers. THP-1 cells like MDMs allow intracellular 
growth of mycobacteria which can be eliminated by incubation of isoniazid.69  Also, THP-1 
cells can model an infection-induced apoptosis response of primary human alveolar 
macrophages which are believed to be the innate defense to eliminate intracellular bacilli.70 
Therefore, THP-1 cells were selected as a model cell line in the study to predict in-vivo 
disposition and efficacy of isoxyl. 
The infected animal model is employed to test drug efficacy in-vivo. The mouse model is 
most commonly used, which is economical, easy to handle, resulting in a highly reproducible 
infection. The model has been developed thoroughly: there are plenty of immunological 
agents and genetic manipulation is available to study immune response in mouse. The mouse 
like the healthy human is more resistant to mycobacteria than guinea pig and rabbit. The 
mouse is different from the human in response to tuberculosis infection in several ways: 1) 
The structure of granulomas in the mouse, unlike the human, are not organized (macrophages 
are surrounded by a ring of lymphocytes);71 2) The mouse does not develop measurable 
delayed-type hypersensitivity after infection, so it does not develop caseous necrosis and 
cavity commonly seen in human.72 Therefore, the immune response in mouse can be very 
different to that in human. The lungs are the natural route of infection following aerosol 
exposure to mycobacteria. This is achieved in the mouse by a nose-only or whole-body 
exposure chamber. However, this method of exposure may lead to variation in the number of 
mycobacteria deposited in the lungs. Alternatively, intravenous injection of mycobacteria 
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may be used to infect the mouse, which results in much higher loads of bacteria seeded in the 
spleen and the liver than the lungs (~ 1%) which does not resemble the natural way of 
disease development.73 As a good alternative animal model, the guinea pig develops disease 
and an immune response similar to the human after exposure to low inocula of mycobacteria. 
The guinea pig develops delayed-type hypersensitivity and caseous necrosis. It also 
experiences hematogeneous dissemination after primary infections like human. As a result, 
guinea pigs develop classic human granuloma, primary and second lesions. Unlike the 
majority of healthy human subjects that have been exposed to mycobacteria without 
developing disease, guinea pigs are more susceptible to mycobacteria and finally die of the 
active disease.71 Also, guinea pigs rarely develop cavities.74 Therefore, guinea pig is a 
sensitive model to evaluate effectiveness of chemotherapy and vaccines. The main drawback 
of the model is that there are a limited number of immunologic reagents commercially 
available. The rabbit can develop disease by a way closer to that of human than mouse and 
guinea pig. It can contain mycobacteria, and develop similar granuloma and chronic cavities 
to human71. However, cost and scarcity of immunologic reagents are always concerns. The 
non-human primate is the closest to human. Moreover, a large number of immunologic 
reagents for the non-human primates are commercially available.  However, practical issues, 
such as availability of animals, facilities, high cost of labor, and higher variability due to 
outbreeding, greatly narrow application of the non-human primate model.73, 75 Consideration 
of all of these issues, the guinea pig model has been used in our lab to test drug sensitivity. 
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1.2 HYPOTHESIS AND SPECIFIC AIMS 
It is postulated that isoxyl particles will significantly reduce the number of viable 
mycobacteria in cell culture, indicating potential efficacy of the drug particles after being 
deposited in the lungs of infected guinea pigs.  
 
Specific aim 1: To develop and validate a quantitative analytical method for 
determination of isoxyl concentrations in plasma following i.v. and oral administrations. 
 It was proposed that poor therapeutic outcomes of isoxyl were caused by low in-vivo 
exposure of the drug. However, most studies of isoxyl were performed four decades ago, so a 
reliable quantification method for determination of this drug concentrationa in biological 
samples was not available. Consequently, the reports of in-vivo behavior of the drug were 
very scarce and controversial. Development of a sensitive and accurate analytic method to 
determine isoxyl concentrations in plasma is a prerequisite to understand the mechanism of 
poor therapeutic outcomes. In this study, a HPLC assay was developed and validated. The 
method was utilized to determine plasma concentrations of isoxyl at various time points after 
it was administered by i.v. administration and the oral route. The relationship of 
concentration-time data was fitted to noncompartment models using WinNonlin analysis 
program to determine the pharmacokinetic parameters.  
 
Specific aim 2: To optimize particle processing conditions to prepare isoxyl particles 
suitable for pulmonary delivery. 
Particle size affects drug deposition to the lungs and in-vivo drug disposition. 
Theoretically, particles, aggregates or droplets with an aerodynamic diameter between 1 to 5 
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µm can penetrate deeply to the lungs. The purpose of the study was to prepare microparticle 
or nanoparticle aggregates in the respiratory size range which can be delivered from a dry 
powder inhaler (DPI) or to produce nanosuspension that can be delivered by nebulizer. After 
these particles deposit on the lung surface, microparticles or nanoparticles may exhibit 
different cytotoxicity and efficacy against intracellular MTB bacilli because of potentially 
different disposition pathways. The goals were to produce both macroparticles with 
diameters between 1-5 µm and nanoparticles with diameters less than 500 nm. The effect of 
processing parameters during antisolvent precipitation and subsequent spray drying were 
studied using statistical experimental design methods. Batches of isoxyl particles with 
desired particle sizes were then prepared by optimizing parameters of manufacture. The 
resulting particles were characterized in terms of their particle size distribution (PSD), 
morphology, polymorphism and fine particle fraction. 
 
Specific aim 3: To assess cytotoxicity of isoxyl particles on human macrophages, and the 
efficacy of these particles on intracellular growth of a model mycobacterium, BCG, in 
these phagocytic cells. 
PMA-differentiated human monocytic THP-1 cells were used as a model of human 
macrophages. Two different isoxyl preparations, spray-dried isoxyl microparticles and isoxyl 
in 1% DMSO, were tested in terms of cytotoxicity and in-vitro efficacy. Preparation of isoxyl 
in 1% DMSO at higher concentrations produced nanoparticles detected by dynamic light 
scattering (DLS). The difference in cytotoxicity of these microparticles and 
nanoparticles/drug molecules was determined by measuring cell viability (Methylthiazol 
Tetrazolium Assays) and integrity of cell membrane (Lactose Dehydrogenase Assays) after 
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the cell monolayers were exposed to these drug preparations. The macrophages were infected 
with Mycobacterium bovis, Bacille Calmette-Guerin (BCG). Comparison of the efficacy of 
these microparticles and nanoparticles/drug molecules was evaluated in-vitro by determining 
viability of the intracellular bacilli after BCG-infected cells have been exposed to various 
forms of the drug. 
  
 
 
Chapter 2 
Development and Validation of Quantitative Analytical 
Method for Determination of Isoxyl Concentrations in Plasma 
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2.1 INTRODUCTION 
Isoxyl was abandoned forty years ago due to failure of early clinical trials. Poor 
solubility in water appeared to contribute to malabsorption of the drug following oral 
administration. Due to the absence of a sensitive and accurate quantitative method, the 
studies of in-vivo exposure to the drug were rare and unreliable. The exact mechanism of 
poor clinical outcomes remains unclear.  
Since most studies of isoxyl were conducted in 1960s and 1970s, only two 
quantitative analytical methods have been reported, microbiological and radiochemical 
methods. The microbiological activity method was insensitive and the radioactive labeling 
method could not distinguish between intact drug and metabolites. Consequently, limited in-
vivo exposure to isoxyl was reported and the data were inconsistent. Published isoxyl blood 
levels after oral administration are summarized in Table 1. Robinson et al.76 reported that 
absorption of isoxyl was rapid, achieving plasma levels significantly higher than MIC (0.4 
µg/ml), but highly variable based on the microbiological method. When a single 9 g dose of 
isoxyl was given orally to 9 human subjects in the fasting state, 5 subjects achieved 
maximum drug concentrations > 128 µg/ml at 2 h, and the remaining 4 subjects obtained a 
peak concentration of 8 to 24 µg/ml, after 2 to 6 h. The average isoxyl blood concentrations 
at specific time points are shown in Figure 3A. In contrast, the other two studies revealed that 
isoxyl was absorbed to a smaller extent using the same method. Eule et al.77 gave two doses 
of 3 g of isoxyl tablets with a 6-hour interval to 31 tuberculosis patients. The average drug 
concentration in serum reached a peak of 5.5 µg/ml 9 h after the first dose [Figure 3B]. This 
low level of isoxyl was comparable to another study in 12 healthy volunteers 78, 79, in which 
drug tablets were administered in two doses of 3 g with 4-hour interval. The maximum isoxyl 
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concentrations determined by both microbiological activity and radioactive labeling were 
approximately 10 µg/ml at 10 h [Figure 3C]. Also, as shown in Table 1, the study performed 
by Eule et al.77 indicated more rapid elimination and isoxyl plasma levels dropped below the 
MIC in less than one day, while the other two studies showed that the drug was eliminated 
slowly and drug concentrations were still higher than MIC after one day. Since these studies 
were carried out under several different conditions, such as dose, dosing regimen, dosage 
form, fasting vs. non-fasting, healthy subjects vs. tuberculosis patients, small vs. large 
population sample sizes, and serum vs. blood samples, comparison is difficult. Further 
studies are necessary to elucidate the in-vivo disposition of isoxyl. In addition, according to a 
study of isoxyl distribution in rabbits, the drug was poorly absorbed and was eliminated in 
bile at a fairly high level. After oral administration of drug at a single dose of 200 mg/kg 
(isoxyl suspension) to rabbits, about 60 % of isoxyl was recovered in feces in 3 days. The 
highest level of isoxyl accumulated in bile, followed by kidney, spleen and liver respectively. 
Lungs and blood showed relatively low drug concentrations 80[Figure 4]. 
To understand the mechanism of poor in-vivo efficacy of isoxyl, an HPLC method 
was developed and validated to determine the isoxyl concentrations in guinea pig plasma and 
preliminary pharmacokinetics of the drug was reported from a pilot study. 
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Table 1. Summary of blood levels of isoxyl delivered orally in human subjects.76-79 
Source Robinson et al.76 Eule et al.77 Lambelin et al.79 
Route (Form) Oral (Not mentioned) Oral (Tablets) Oral (Tablets) 
Dose Single, 9 g 2×3 g (6 h) 2×3 g (4 h) 
No. of patients 9 31 6 
Subjects Healthy, fasting Patients Healthy, non-fasting 
Samples 
analyzed Blood Serum Blood 
Assay Method Microbiological Microbiological Microbiological and Radioactive 
MIC 0.4 µg/ml 0.6-0.8 µg/ml 1.2-1.4 µg/ml 
Time (C<MIC) >24 h < 24 h > 24 h 
Cmax (Tmax) 
>128 µg/ml (2 h) in 5 
subjects 
8-24 µg/ml (2-6 h) in 
4 subjects 
5.5 µg/ml (9 h after 
first dose) 
8-11 µg/ml  (~ 10 h 
after first dose) 
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Figure 3. (A) Mean blood concentrations of isoxyl at various periods after a single dose of 9 
g to 9 human subjects, 5 of whom exhibited peak levels over 128 µg/ml.76 (B) Mean serum 
concentrations of isoxyl at various periods after two doses of 3 g tablets at 6-hour interval to 
31 tuberculosis patients.77 (C) Mean blood concentrations of isoxyl determined by 
radioactive labeling method (closed circles) and microbiological activity method (open 
circles) at various periods after two doses of 3 g tablets to 6 patients at 4-hour interval. 78, 79 
The dotted lines represent MIC of isoxyl in the studies. (Figures prepared from data in 
references 76-79) 
 
2.2 RATIONALE AND EXPERIMENTAL DESIGN 
The analysis was performed using a Hewlett Packard 1100 series HPLC (Agilent 
Technologies, Santa Clara, CA) with a binary pump, an autosampler, a Waters Spherisorb 
5µm ODS2 (4.6×150 mm) analytic column preceded by a Nova-Pak C18 4µm precolumn 
cartridge, and a UV detector set at 270 nm (the absorption maximum wavelength of isoxyl in 
acetonitrile). A narrow-bore column, Spherisorb 5µm ODS2 (2×100 mm), was employed 
owing to increase detectability, less consumption of solvents, and short run time. N,N'-bis[4-
Time (h)
0 5 10 15 20
Is
ox
yl
 B
lo
od
 C
on
ce
nt
ra
tio
n 
(u
g/
m
l)
0
2
4
6
8
10
12
 
Time (h)
0 5 10 15 20
Is
ox
yl
 S
er
um
 C
on
ce
nt
ra
tio
n 
(u
g/
m
L)
1
2
3
4
5
6
 Time (h)0 20 40 60
Lo
g 
Is
ox
yl
 B
lo
od
 C
on
ce
nt
ra
tio
n 
(u
g/
m
l)
0.1
1
10
100
 
A B
 C 
 24
(1,1-dimethylethyl)phenyl]-thiourea [Figure 1B], having similar structure to isoxyl, was 
chosen as an internal standard to compensate for variations in sample preparation and 
injection procedures. The method was validated according to FDA guidance for bioanalytical 
method validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory 
Information/Guidances/UCM070107.pdf). 
 
Figure 4. Thiocarlide (isoxyl) concentration determined by 35S-concentration after a single 
oral dose of 200 mg/kg 35S-thiocarlide to rabbits. Microbiological comparison was measured 
after the last dose of 100 mg/day thiocarlide for 9 days.80 (Figures prepared from data in 
reference 80) 
 
Isoxyl was administered to guinea pigs by i.v. administration. After the treatment, blood 
samples were collected at various time points and drug concentrations were determined by 
the HPLC assay. Pharmacokinetic (PK) parameters were determined from plasma 
concentration vs time data. The disposition of isoxyl following oral delivery was also 
determined. If the drug plasma concentrations are low, this explains the poor therapeutic 
outcomes of isoxyl following oral delivery. Further studies will be focused on measuring 
drug concentrations in the lungs after inhalation of isoxyl. 
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2.3 MATERIALS AND METHODS  
2.3.1 Materials 
 Isoxyl was purchased from Cayman Chemical Co. (Ann Arbor, Michigan). 
Acetonitrile (HPLC grade) and ammonium acetate (HPLC) were obtained from Acros 
Organics and Fisher Scientific respectively. Carboxymethyl cellulose, sodium salt (CMC) 
was from Sigma. N,N'-bis[4-(1,1-dimethylethyl)phenyl]-thiourea (internal standard, IS) were 
from Ryan Scientific, Inc (Mt. Pleasant, South Carolina). Dunkin-Hartley guinea pigs were 
purchased from Hilltop Lab Animals Inc. (Scottsdale, PA). Blood was collected at different 
time points and plasma was separated, and stored at -80oC until use. Ultrapure water was 
obtained from Barnstead Nanopure Infinity Ultrapure Water System (Dubuque, IA, USA). 
 
2.3.2 Preparation of the Standards and Quality Control (QC) Samples 
A 2 mg quantity of isoxyl was weighed accurately and then transferred to a 2 ml 
volumetric flask containing ethanol. The stock solutions of isoxyl at nominal concentrations 
of 0.100, 0.0100, 0.00100 mg/ml were made by a series of 10-fold dilutions using volumetric 
flasks. These solutions were stored at - 20 oC until use. From these stock solutions, norminal 
concentrations of 0.0500, 0.100, 0.250, 0.500, 1.00, 2.50, 5.00, 10.0, 25.0, 50.0 µg/ml isoxyl 
were made freshly using either 50% Acetonitrile (ACN) in 20 mM ammonium acetate buffer 
or guinea pig plasma to obtain the standards.  Three quality controls were made by spiking 
plasma with isoxyl to prepare solutions at concentrations of low (0.400 µg/ml), medium (6.00 
µg/ml) and high (40.0 µg/ml). The standards and quality controls in plasma were stored at -
80 oC until analysis. 
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2.3.3 Analytical conditions 
Mobile phase was screened by varying ratios of acetronitrile to water. Flow rate was 
0.5 ml⋅min-1. The optimal analysis condition was determined by running time and separation 
of isoxyl and internal standard. The standards containing pure isoxyl in 50% ACN and 50% 
20 mM ammonium acetate buffer were used to determine linearity of the drug in a range of 
concentrations. Background levels were measured and the limit of detection (LOD) was 
measured by signal to noise ratio of 3. 
 
2.3.4 Extraction of Isoxyl from Plasma 
Internal standard (0.102 mg/ml) of 5 µl were spiked in 100 µl of the standards, QCs, 
blank plasma controls and samples. Acetonitrile (400 µl) was then added to precipitate 
proteins. The samples were vortexed for 2 min and centrifuged at 12,000 rpm for 10 min. 
The supernatants were pipetted into microcentrifuge tubes and dried in a Savant ISS110 
Speedvac concentrator (Thermo Fisher Scientific, Waltham, MA). Each pellet was dissolved 
in 100 µl of 50% acetonitrile in 20 mM ammonium acetate buffer from which 50 µl was 
injected.  
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2.3.5 Method Validation 
Briefly, specificity was evaluated by separation of the isoxyl peak from the peaks of 
impurities from plasma and internal standard. The standard curve was plotted by peak area 
ratios of isoxyl to internal standard against isoxyl concentrations. The best fit line was 
obtained by the least regression method and the regression coefficient (R2) was calculated. 
Intra-day precision and accuracy of the HPLC method were evaluated by assaying at least 
four replicates of standard plasma solutions at three concentrations, low (0.400 µg/ml), 
medium (6.00 µg/ml) and high (40.0 µg/ml) in one day. The inter-day variation was 
determined by assaying these three concentrations on each of five consecutive days. The 
limit of quantification (LOQ) was measured by determining precision and accuracy of five 
replicates of four low concentrations, 0.0500, 0.100, 0.250, and 0.500 µg/ml.   
 
2.3.6 Recovery Evaluation  
Extraction efficiency was defined as the amount of the drug extracted from plasma 
expressed as a percentage of the amount of the drug in the pre-extraction sample (control). 
Samples of 0.400, 6.00, 40.0 µg/ml in triplicate were extracted and analyzed by HPLC as 
described in above. For controls, drug free plasma of 100 µl was extracted with 400 µl 
acetonitrile, as described in sample preparation. Isoxyl and 50% acetonitrile in 20 mM 
ammonium acetate buffer were added to the extraction pellets to prepare controls of 0.400, 
6.00, 40.0 µg/ml. All the controls were assayed in triplicate. An internal standard was 
introduced into each sample and control. The recovery of isoxyl from plasma was evaluated 
by comparing peak area ratios of isoxyl to internal standard measured in samples with those 
of the controls of the respective concentrations. 
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2.3.7 Stability Studies 
The stability of isoxyl was evaluated by determining the drug concentration change in 
quality control samples (QCs) during storage. Triplicate QCs were stored at room 
temperature for 5.5 h or underwent three freeze-thaw cycles according to FDA guidance. For 
long-term stability, the standards were stored at   -80 oC for a month (30 days).  
 
2.3.8 Preliminary Pharmacokinetic Studies 
 Male Dunkin-Hartley guinea pigs (808-961 g) were employed. All of the animal 
experiments were consistent with the policies of the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee. The right external jugular vein of each 
guinea pig was cannulated under anesthesia (ketamine 50 mg/kg and xylazine 5 mg/kg) using 
silicone polymer tubing connected to polyethylene PE-50 tubing to facilitate collection of 
blood samples. Two guinea pigs received a dose of 10 mg/kg or 20 mg/kg by intravenous 
administration through the cannula implanted in the jugular vein. Blood samples were 
collected at various time points and drug concentrations were determined by the HPLC assay. 
The 10-min infusion at a dose of 8.7 mg/kg was performed to prevent isoxyl from 
precipitation immediately after injection and to obtain accurate pharmacokinetic parameters. 
For oral delivery, isoxyl was suspended in 1% CMC and ground in a mortar with a pestle. 
The suspensions were fed orally to guinea pigs in duplicate at a dose of 100 mg/kg. 
The isoxyl plasma concentrations vs. time data were analyzed by the WinNolin 
computer analysis program (Pharsight Corp., Mountain View, CA) using noncompartmental 
model. Pharmacokinetic parameters of isoxyl were calculated. 
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2.4 RESULTS  
Optimization of chromatographic methods was conducted using samples containing 
the pure drug solution in 50% ACN and 50% 20 mM ammonium acetate buffer. The 
optimized mobile phase contained 70% ACN and 30% 20 mM ammonium acetate buffer. 
The retention times of internal standard and isoxyl were 3.5 min and 4.5 min respectively 
[Figure 5A]. As the percentage of ACN in mobile phase increased to 75%, isoxyl peak 
merged with internal standard peak. Decrease of ACN resulted in the longer retention time 
(TR). When a volume of 10 µl of the samples was injected onto the HPLC column, a linear 
calibration plot of isoxyl ranging from 0.1 µg/ml to 50.6 µg/ml was obtained. The regression 
equation and correlation coefficient were determined:  
Peak Area Ratio (Isoxyl/IS) =0.173×Concentration (µg/ml) -0.0044 [R2=0.9960]  
The Limit of detection (LOD) of the method was determined to be 20 ng on the Waters 
Spherisorb 5µm ODS2 (4.6×150 mm) analytic column. 
For plasma samples, isoxyl was extracted with ACN and analyzed by HPLC. Isoxyl 
peak (4.8 min) was separated well from the peaks of internal standard (3.8 min) and 
impurities from plasma (1.2 min) [Figure 5B]. The chromatogram of blank guinea pig plasma 
showed only the peak of impurities from plasma [Figure 5C]. The LOQ was determined to be 
0.25 µg/ml based on intra-day variation (precision was < 20% and accuracy was between 
80% and 120%) and the recovery of isoxyl extracted by ACN was above 68% [Table 2-3]. 
The standard curve of isoxyl was linear from 0.25 µg/ml to 50 µg/ml:  
Peak Area Ratio (Isoxyl/IS)=0.20×isoxyl concentration (µg/ml) -0.023  [R2=0.9958]  
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Figure 5. (A) A chromatograph of isoxyl (4.5 min) and internal standard (3.5 min) dissolved 
in ethanol. (B) A representative chromatogram of isoxyl (4.8 min, 10.3 µg/ml) and internal 
standard (3.8 min, 5.0 µg/ml) extracted from guinea pig plasma (wavelength=270 nm). (C) A 
chromatogram of blank guinea pig plasma. 
 
                 Table 2. Determination of Limit of Quantification (LOQ) (n=5). 
Conc. (µg/ml) Precision (%) Accuracy (%) 
0.0504 43 259 
0.101 40 108 
0.252 11 87 
0.504 12 100 
 
Table 3. Determination of extraction efficiencies in three concentrations (n=3). 
Conc. (µg/ml) Recovery (%) 
0.404 77 ± 13 
6.05 68 ± 13 
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As shown in table 4, the HPLC method was validated for determining isoxyl 
concentrations in plasma: 1) Intra-day and inter-day precision of the method were between 
6.8-14% for 0.400 µg/ml and between 6.0-8.0 % for 6.00 and 40.0 µg/ml; and 2) Intra-day 
and inter-day accuracy of the method were between 115-119% for 0.400 µg/ml and between 
85-99% for 6.00 and 40.0 µg/ml [Table 4]. The HPLC analysis demonstrated that isoxyl was 
stable under the conditions employed. Isoxyl concentrations in the plasma samples did not 
change after being frozen and thawed for three cycles or kept at room temperature for 5.5 h 
[Table 5]. Also, isoxyl was stable after the plasma samples were stored at - 80 oC for one 
month [Table 6].   
Pharmacokinetic parameters were first determined by intravenous administration of 
isoxyl to guinea pigs. Two doses of isoxyl (10 and 20 mg/kg) exhibited the same plasma 
concentration vs. time profiles: the initial concentration of isoxyl in blood circulation was 12-
14 µg/ml and the drug was rapidly eliminated to a concentration below MIC (2 µg/ml) in 1 h 
[Figure 6A and Table 7]. The 10 min infusion did not increase in-vivo exposure of isoxyl 
[Figure 6B]. When isoxyl was administered orally, the drug plasma concentrations at various 
time points were far below the reported MIC (2 µg/ml). Most of them were also below the 
limit of quantification (LOQ) [Figure 6C].   
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 Table 4. Intra-day and inter-day variations (n=4 for each concentration). 
Intra-day Inter-day Spiked 
Conc.  
(µg/ml) 
Measured 
Conc. 
(µg/ml) 
Precision 
(%) 
Accuracy 
(%) 
Measured 
Conc. 
(µg/ml) 
Precision 
(%) 
Accuracy 
(%) 
0.412 0.47 6.8 115 0.49 14 119 
6.18 5.5 7.5 89 5.22 6.0 85 
41.2 39.0 7.3 95 41.0 8.0 99 
 
Table 5. Stability of isoxyl under room temperature (benchtop) and freeze/thaw conditions. 
 Time Period Spiked Conc. (µg/ml) % of Control 
0.412 115 ± 21 
6.18 85 ± 1.5 Benchtop (n=3) 5.5 h 
41.2 104 ± 3.2 
0.412 105 ± 12 
6.18 112 ± 12 Freeze/Thaw (n=3) 3 cycles 
41.2 107 ± 10 
 
Table 6. Long-term stability of isoxyl under frozen conditions. 
 Time Period Sample Conc. (µg/ml) % of Control 
0.510 82 
10.3 119 
25.7 96 
Storage at - 80oC One month 
51.5 114 
 
Table 7. Pilot study of Pharmacokinetic parameters after i.v. administration. 
Dose (mg/kg) C0 (µg/ml) CL (L/h/kg) Vβ (L/kg) λ(h-1) AUC (µg⋅h/ml) 
10 12.83 1.21 2.45 0.49 8.26 
20 12.27 2.23 8.28 0.27 8.95 
* C0: initial concentration, CL: clearance, Vβ: volume of distribution of the terminal phase,  
λ: elimination rate constant, AUC: area under plasma concentration vs. time curve. 
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Figure 6. Plasma concentration versus times profiles study of isoxyl after it was given by i.v. 
bolus administration (A), by a 10-min infusion (B), and oral administration (C). The dotted 
line in black represents MIC and the lower line in dark gray is limit of quantification (LOQ). 
 
Time (h)
0 2 4 6 8
Is
ox
yl
 P
la
sm
a 
C
on
ce
nt
ra
tio
n 
(u
g/
m
L)
0
1
2
3
4
5
100 mg/kg in 1% CMC
100 mg/kg in 1% CMC
C 
A B 
Time (h)
0 2 4 6 8
Is
ox
yl
 P
la
sm
a 
C
on
ce
nt
ra
tio
n 
(u
g/
m
L)
0
2
4
6
8
10
10 mg/kg in EtOH
20 mg/kg in EtOH/DMSO=3/1
 Time (h)
0 2 4 6 8 10 12
Is
ox
yl
 P
la
sm
a 
C
on
ce
nt
ra
tio
n 
(u
g/
m
L)
0
1
2
3
4
5
7.3 mg/kg in EtOH 
 
 34
2.5 DISCUSSION 
An optimized reverse-phase HPLC method was developed to determine isoxyl 
concentrations in plasma. The method was a simple procedure with good peak resolution and 
short run-time. The method was precise, accurate and robust with a sufficiently low limit of 
quantification as defined by the FDA guidance. Based upon reported MIC, a LOQ of 0.25 
µg/ml was adequate since it is about eight-fold lower than the MIC (2 µg/ml) in plasma. 
The HPLC method was utilized to determine the preliminary pharmacokinetic 
profiles of isoxyl after it was given to guinea pigs by intravenous administration. The low 
and high doses exhibited similar isoxyl plasma concentration vs. time profiles, i.e. the same 
initial concentration (C0) and AUC. This suggested that the distribution of isoxyl seemed a 
solubility-limited process even for direct administration of the drug. Precipitation near the 
site of injection is likely to have occurred after administration. Consequently, the 
pharmacokinetic parameters may be inaccurate. To obtain reliable pharmacokinetic 
parameters of isoxyl, slower infusion was conducted, but it may not have been sufficiently 
slow to prevent precipitation of the drug at the site of administration. Further investigation of 
extended infusion times to accommodate the dosing requirements for this sparingly soluble 
drug are required to evaluate disposition of drug from the circulation. 
Isoxyl has been shown to be active in animals and humans at an oral dose of 100 
mg/kg. Indeed, some reports suggest that a dose of 50 mg/kg is effective in therapy in guinea 
pigs.18 In the present study, a 100 mg/kg dose of isoxyl was delivered orally to guinea pigs. 
However, this dose of drug did not approach the MIC for Mycobacterium tuberculosis in the 
circulation, as estimated from drug concentrations in plasma. It may be inferred that the 
equivocal therapeutic outcome observed in some clinical trials may be a result of poor 
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bioavailability of isoxyl following oral delivery. Surprisingly, the previous reports detected 
much higher drug concentration than the MIC where the peaks of isoxyl concentration in 
plasma varied from 5 to 108 µg/ml.76-79 In these studies, either microbiological or 
radiochemical methods were employed to determine drug concentrations in blood or serum. 
The poor bioavailability has several possible explanations. Firstly, isoxyl might be 
transformed to some active metabolites in-vivo which cannot be differentiated from the 
parent compound by HPLC with UV detection, since they may be hydrophilic and mixed 
with co-eluting impurities from plasma, but may be detected by both microbiological and 
radiochemical methods. In this scenario, depending on the activity of the metabolites, 
individual differences in patient metabolism of isoxyl could result in highly variable 
therapeutic outcomes. Guinea pig liver microsomes could be used to study metabolism of 
isoxyl and identify these possible active metabolites. Considering the tedious, costly and 
high-risk drug discovery process, in-vitro metabolism may provide a rapid way to develop 
new anti-tuberculosis drug alternatives with improved physico-chemical properties and 
metabolic profiles. An alternative explanation for the differences in bioavailability is species 
specific factor. It has been reported that isoxyl blood levels in rabbit were significantly lower 
than those in humans.78 But this low drug exposure was apparently sufficient to treat 
tuberculosis in rabbits. Efficacy of isoxyl in the infected guinea pig and human has also been 
demonstrated.18, 20, 81, 82 Therefore, concentration difference of isoxyl in different species may 
not be a critical factor. The formulation of the dosage form for oral delivery of isoxyl might 
also play a role in drug availability by influencing dissolution rate. However, isoxyl tablets, 
which require disintegration and deaggregation prior to dissolution, have been shown to 
achieve plasma concentrations which were far above MIC.77-79 In the present study, drug was 
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prepared as a suspension by levigating in 1% carboxymethylcellulose solution. The 
suspension, with large surface area for dissolution, should exhibit more rapid dissolution than 
tablets, and, potentially higher bioavailability (rapid uptake, larger peak plasma 
concentration). 
It is anticipated that isoxyl concentrations in the lungs would be low following oral 
administration. Meissner et al. gave 35S-thiocarlide to rabbits and detected isoxyl 
concentrations in various organs. The drug concentration in the lungs was close to that in 
blood.80[Figure 4] In the present study since isoxyl plasma concentrations following oral 
administration were below the LOQ (< MIC) in guinea pigs, it is likely that the isoxyl 
concentrations in the lungs were also less than MIC from 0 to 24 h after drug administration. 
Also, it is probable that only small quantities of circulating isoxyl can penetrate to 
granulomas, tubercles or lesions that receive poor blood supply. These barriers to drug 
delivery would result in extremely low doses of isoxyl arriving at the main site of infection 
and would contribute to the failure of clinical trials. 
There are several possible mechanisms for poor clinical outcomes of isoxyl. Two 
approaches can be applied to rescue this drug, seeking alternative routes of administration or 
developing better analogues based on the study of in-vitro or in-vivo metabolism of the drug.  
Pulmonary delivery of isoxyl is a promising alternative as: 1) much higher concentrations of 
isoxyl are delivered to the lungs and are retained for an extended period of time at the main 
site of infection; and 2) isoxyl paricles, due to their slow dissolution, may be taken up by 
alveolar macrophages which are host cells for TB bacteria and have local action, or be 
translocated by these cells to granulomas, lymph nodes or other major sites of infection 
where drug would be released.  
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2.6 CONCLUSIONS 
A reliable reverse-phase HPLC method was developed for determination of isoxyl 
concentrations in plasma. The method was used to perform preliminary pharmacokinetic 
studies of isoxyl after it was administered intravenously and orally. Interpretation of previous 
reports in the context of the initial pharmacokinetic assessment in these studies, suggests that 
previous therapeutic failures or conflicting clinical trials outcomes of isoxyl may have been 
due to either poor absorption of the drug or variation in formation of active drug metabolites. 
Pulmonary delivery of isoxyl and development of active metabolites may be promising 
approaches to rescue this abandoned drug and render it an effective agent for treatment of the 
serious MDR TB disease. This study focused on generating isoxyl aerosols for lung delivery. 
 
  
 
 
Chapter 3 
Preparation of Isoxyl Microparticles and Nanoparticles for 
Pulmonary Delivery 
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3.1 INTRODUCTION 
Low solubility is one primary cause for the previous poor therapeutic outcome of isoxyl 
following oral administration. Similarly, many active compounds that have been discovered 
that were subsequently abandoned due to poor solubility. However, improvement of their 
performance by modifying their chemical structures is laborious and costly. 83, 84 Discovery 
and marketing of a new drug usually takes billions of dollars and up to 15 years.85 Therefore, 
seeking an optimal formulation and desirable dosage forms for these drugs will be the most 
convenient and cost effective approach. Many methods such as co-solvents, surfactants, 
emulsions, or polymer complexation can be employed to increase solubility. Though there 
are some successful cases, the low drug loadings and the toxicities of the excipients are 
always concerns.84, 86 Moreover, even if oral absorption can be improved by these methods, 
the fraction of isoxyl which reaches the granulomas, tubercles or lesions is very limited. 
Formulation of micrometer or nanometer-sized isoxyl particles would be a simpler and safer 
method to improve efficacy of the drug. These particles can be delivered to the lungs which 
increases drug concentration at the main site of infection. A fraction of these drug particles 
can target macrophages in the lungs, the host cells for mycobacteria. Meanwhile, large 
surface area of these particles and hydrophobic environment in the lung lining fluid may 
potentially increase systemic exposure of the drug to eliminate extrapulmonary mycobacteria.  
Many approaches have been utilized to prepare microparticles or nanoparticles of 
therapeutic drugs. A widely used approach is to break up drug particles by mills. However, 
milling requires long process time, and also may cause contamination with impurities and 
formation of amorphous drugs. Compared to milling, antisolvent precipitation is simple, and 
it can control the crystallinity of drugs and produce high drug loading. Preparation of 
 40
micrometer or nanometer-sized pure drug particles would also be safer than formulation with 
a large quantity of excipients to increase solubility. The mechanism of precipitation includes 
three processes, nucleation, coagulation, and condensation. Addition of antisolvent to the 
drug solution creates high degree of local supersaturation, which leads to the formation of 
many small nuclei. The rate of primary nucleation (homogenous nucleation) J is described by 
the following equation 4: 
                                          ⎥⎦
⎤⎢⎣
⎡−= 233
23
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16
exp
STk
V
AJ m
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                                            [4] 
Here, A is a constant, γ is interfacial tension, Vm is molecular volume, k is Boltzmann 
constant, T is the absolute temperature, and S is degree of supersaturation (S is equal to ratio 
of the solution concentration to the equilibrium saturation at the given temperature).87, 88 
These nuclei then undergo growth by condensation and coagulation until an equilibrium in 
which particle sizes are not changed. 86 Therefore, the solid-state properties including particle 
size distribution (PSD) and morphology of the resulting precipitants can be influenced by the 
factors that have impact on the rates of these three processes. For example, different solvents 
can change the crystal habits due to their physiochemical properties; higher temperature may 
result in larger particle size owing to increasing solubility, diffusion and growth kinetics; 
increase of antisolvent introduction rates tends to produce more needle-like crystals with 
smaller particle size and a more narrow distribution; higher degree of miscibility of 
antisolvent and solvent increases mixing rate and results in smaller crystal sizes; the mixing 
method with higher energy can also yield smaller particles. 86, 89  
Spray-drying has been used to produce powders for pulmonary delivery due to its ease of 
operation and ability of controlling particle characteristics. In the following study, this 
method was applied to dry the particle suspension generated from anti-solvent precipitation. 
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The suspension is atomized into a spray by a gas under pressure and mixed with hot air 
stream in the drying chamber. The solvents are evaporated. The resulting solid particles are 
moved along with air stream and separated from the air in cyclone and collecting vessel. In 
the spray-drying process, particle size and shape can also be changed by varying feed 
properties, atomization conditions and drying process.90 Theoretically, larger particles are 
produced when nitrogen flow rate is slower, organic strength of the solvent decreases, feed 
rate is more rapid and drug solution is more concentrated. Particle shape is affected by 
physicochemical properties of the feed solvent and outlet drying temperature. 
Therefore, it is expected that the study of antisolvent precipitation and spray drying 
conditions of isoxyl would permit production of particles with diverse PSDs and other 
characteristics. The future efficacy study of these different particles will help to identify the 
optimal particle characteristics for treating TB disease. 
 
3.2 EXPERIMENTAL DESIGN 
 The purpose of the study is to produce particles with different sizes for pulmonary 
delivery. The goal of particle preparation is to produce microparticles with diameters 
between 1 to 5 µm which is suitable for pulmonary delivery and generate nanoparticles with 
diameters less than 500 nm. Nanoparticles can be delivered in the forms of suspensions, 
aggregates or particles in matrix. A modified BUCHI B-191 mini spray-drier containing a 3-
fluid nozzle was used to produce isoxyl particles. The nozzle allows water, isoxyl in organic 
solvent and compressed nitrogen pass independently. The two liquid feeds are mixed and 
atomized at the tip of the nozzle, where antisolvent precipitation occurs. The precipitants 
generated by this process are controlled by several variables: inlet temperature, type of 
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organic solvent, various ratios of organic solvent to water, and mixing energy (nitrogen flow 
and feed flow).86, 89 The precipitants were then spray dried. According to the information 
provided by Buichi Labortechnik AG, particle size resulted from the following spray drying 
process is influenced by four main variables: spray flow rate and pressure, organic feed rate, 
organic solvent type, and isoxyl concentration. Consequently, isoxyl particle preparation 
consists of two processes, antisolvent precipitation and spray drying, which are controlled by 
totally seven main variables as shown in Table 8. Statistical experimental design (Design 
Expert®, State-Ease, Inc., Minneapolis, MN) is a quick method for optimizing preparation 
conditions by studying the effects of several variables and their interactions concurrently.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Materials 
 Isoxyl was purchased from Cayman Chemical Co. (Ann Arbor, Michigan). Acetone 
and isopropanol were obtained from Fisher Scientific. D-mannitol and ethanol were from 
Sigma. Tetrahydrofuran (THF) was from EM Science (Darmstadt, Germany). Lactose 
(Respitose ® ML001) was provided by DMV international. Flexi-DryTM freeze-drier was 
from Kinetics Group (Santa Clara, CA). The 3-fluid nozzle was purchased from Buchi 
Labortechnik AG (Flawil, Switzerland) and fit in a BUCHI B-191 mini spray-drier made by 
the same manufacturer. Isopore™ Polycarbonate Membrane Filter (Pore size: 0.1 µm, 
Millipore, Billerica, MA) or a Cyclopore Polycarbonate Membrane Filter (Pore size: 0.1 µm, 
Whatman, Florham Park, NJ) were used to collect particles in suspensions. Water was 
deionized by Barnstead Nanopure Infinity Ultrapure Water System (Dubuque, IA, USA). 
Either SEM (JSM 6300V scanning electron microscopy, JEOL USA, Peabody, NY, USA) or 
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SEM (Hitachi S-4700 cold cathode field emission scanning electron microscopy) was used to 
visualize the particles. Laser diffraction (LD, Series 2600C Malvern Instruments, Malvern, 
UK) and Dynamic Light Scattering (Nicomp particle sizing systems, AutodilutePAT Model 
370 Santa Barbara, CA) were utilized to measure microparticle and nanoparticle size 
distributions, respectively. Thermal properties of isoxyl were measured by Differential 
Scanning Calorimetry (DSC, Perkin Elmer DSC 6, Waltham, MA). 
 
3.3.2 Particle Manufacture 
1) Particles Precipitated from the Injection Method: The preliminary screening of 
precipitation conditions was performed by injecting isoxyl (1 mg/ml) solution in ethanol into 
the aqueous phase manually at a speed of approximate 15 ml⋅min-1 during magnetic stirring 
using a 27 gauge sterile needle with a 10 ml disposable syringe. The tip of the needle was 
located just above the stir bar to achieve maximum mixing. Three volume ratios of solvent to 
antisolvent (VRSAs) were assessed, 1:1, 1:2, and 1:5. All the above procedures were 
conducted at room temperature. The resulting isoxyl particle suspensions were centrifuged 
(Beckman Model CS-15R) at 8000-9000 rpm for 10 min and then the supernatants were 
discarded. The pellets were transferred to the freeze-dryer (temperature < -50 oC and pressure 
< 0.05 millibar) and dried for 24 to 48 h.  
 
2) Particles Precipitated from the Nozzle Mixing Method: Solvent and antisolvent 
at a VRSA equal to 1:5 were mixed by a 3-fluid nozzle. Isoxyl concentrations in ethanol, 
isopropanol, acetone and THF were 11 mg/ml, 7 mg/ml, 100 mg/ml and 100 mg/ml 
respectively. This was determined by solubility of isoxyl in these solvents. All the other 
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antisolvent precipitation conditions were kept constant: organic feed rate 0.2 ml/min, water 
feed rate 1 ml/min, nitrogen flow rate 400 L/min and atomization pressure 3 bar.  Atomized 
fine droplets from the 0.7-mm diameter nozzle were sprayed directly into 50 ml quenching 
water. Dynamic light scattering was used to measure particle size distribution in the 
suspensions. The particles in suspension were collected by filtering through a membrane 
filter. The filters were completely dried in a vacuum desiccator and used immediately for 
SEM. 
  
3) Spray-dried Particles from the Nozzle Mixing Method: The effects of 
processing parameters on particle characteristics were evaluated utilizing a 27-4 factorial 
design. Eight manufacturing runs were conducted and randomized by statistical experimental 
design [Table 8]. For all the studies, the aspirator rate of the spray drier was kept at 90% of 
maximum flow (approximately 35 m3·h-1). Water and isoxyl solution in either isopropanol or 
ethanol were sprayed by the 3-fluid nozzle into a BUCHI B-191 mini spray-drier. The 
particles impacted on the bottom of cyclone (<8 cm from the bottom edge) and collecting 
vessel and were collected, and subsequently characterized.  
 
 Table 8. A 27-4 factorial design for isoxyl particle preparations. 
 
Organic 
Solvent 
Organic 
Feed 
(ml/min) 
Water 
Feed 
(ml/min)
Isoxyl 
Conc. 
(mg/ml) 
Inlet 
Temp 
(oC) 
N2 
Pressure 
(bar) 
N2 
Flow 
(L/min)
1 Isopropanol 0.3 1.8 2 120 3 600 
2 Ethanol 0.3 0.7 5 120 6 600 
3 Isopropanol 0.3 0.7 2 100 6 800 
4 Ethanol 0.7 1.8 2 100 6 600 
5 Ethanol 0.3 1.8 5 100 3 800 
6 Ethanol 0.7 0.7 2 120 3 800 
7 Isopropanol 0.7 1.8 5 120 6 800 
8 Isopropanol 0.7 0.7 5 100 3 600 
 
 45
In addition to alcohol, THF as solvent was also evaluated. Isoxyl was dissolved in 
THF at a concentration of 100 mg/ml and spray dried using the following condition: organic 
feed rate 0.5 ml/min, water feed rate 1.8 ml/min, atomization pressure 3 bar, nitrogen flow 
rate 600 L/min and aspirator rate 90% of maximum flow. 
The use of the bulking agent, mannitol, was assessed.  The isoxyl solution (7.2 mg/ml) 
of 4 ml and water were mixed in the 3-fluid nozzle under the following conditions: organic 
feed rate 0.3 ml/min, water feed rate 1.7 ml/min, nitrogen flow rate 400 L/min and 
atomization pressure 3 bar. The mixture was directly sprayed into 200 ml of mannitol 
solution (0.63 mg/ml). This resulted in the ratio of isoxyl to mannitol equal to 1:4.4. The 
dried particles were resuspended in water to dissolve mannitol. Particle size distributions 
were measured by dynamic light scattering. To visualize these particles, the suspension was 
filtered by a membrane filter. The filter was washed with a large quantity of water at least 
three times to remove residual mannitol and then dried in a vacuum dessicator to be ready for 
SEM. 
 
3.3.3 Characterization 
1) Particle size and morphology: The primary particle size, shape and surface 
morphology of the isoxyl particles were examined by SEM. The lyophilized particles and 
commercial isoxyl powders were employed as controls and directly applied to conductive 
double-sided tapes attached to aluminum stubs. The spray-dried particles are first suspended 
in water and sonicated for 30 seconds.  Small drops of the particle suspensions were placed 
on the tape and dried in a vacuum desiccator. The filters containing nanoparticles were cut to 
fit and placed on the tapes. All the samples were sputter-coated using either a Polaron 5200 
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(Structure Probe Supplies, West Chester, PA) or a Cressington 108 with a Cressington 
MTM-10/10A high resolution film thickness monitor (Cressington Scientific Instruments, 
Cranberry, PA) with gold-palladium alloy and micrographs of the particles were taken. The 
primary particle size distributions and circularities were calculated by Image J program 
(Image Processing and Analysis in Java, created by NIH image for Macintosh). Here, the 
circularity indicates degree of particle elongation and a value approaching unity means that 
the particles are nearly spherical. 
LD was used to measure microparticle size distribution, by volume. Briefly, the 
microparticles were suspended in water and sonicated for 1-2 min. The suspensions were 
added dropwise in a stirred sample cell containing distilled water until an obscuration level of 
about 10% to 20% were achieved. Nanosuspensions from precipitation or particle in 
mannitol matrix were redispersed in water and nanoparticle size distributions were measured 
by dynamic light scattering.  
 
2) Thermal Properties of Spray-dried Microparticles: Thermal profiles of 
unprocessed isoxyl powder and a batch of spray-dried isoxyl microparticles (condition 8) 
were subjected to DSC, in which nitrogen at a flow rate of 30 ml/min was the purge gas. The 
samples were sealed in standard aluminum pans and heated from 21 oC to 250 oC at scanning 
rates of 40 oC/min and 5 oC/min. 
 
3) Fine Particle Fraction and Emitted Dose: Aerosolization of the lyophilized 
isoxyl particles from the injection method, the spray-dried particles (condition 8), and control 
from commercial source were determined. Lactose carrier particles were added by mixing 
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isoxyl microparticles at a concentration of 1% w/w (Fischer Scientific hematology/chemistry 
mixer, model 346) for 10 min. Isoxyl powders of approximate 1 mg with or without lactose 
carrier were filled into the gelatin capsule (product size: #3, Capsugel, Reapack, NJ) and then 
placed in an Inhalator® (Boehringer Ingelheim). A twin-stage liquid impinger (TSLI) was 
employed to evaluate deposition of the isoxyl particles. The impinger (7 ml and 30 ml of 
ethanol were placed in the upper and the lower stages) was assembled to be airtight and 
vertical. After turning on the pump providing an air flow of 60 L/min, isoxyl powder was 
released from the inhalator. The pump was turned off 10 seconds after emission. After 
disassembling the apparatus, the capsule shell, the inhaler device, the mouth piece, the throat, 
and the upper and lower stages were all thoroughly washed with ethanol separately. When 
isoxyl was dissolved in ethanol, the absorption maximum wavelength was 273.5 nm. The 
concentration of isoxyl in each sample was determined by UV spectrometry at a wavelength 
of 273.5 nm based on standard curves (R2>0.98). Several parameters of the deposition profile 
of each isoxyl powder were calculated: the emitted dose (ED) is the total drug mass leaving 
the device (the sum of the amount of isoxyl in the mouthpiece, the throat, and the two stages); 
the recovered dose (RD) includes ED and the amount in the capsule shells and the inhalator 
device; the fine particle dose (FPD) is the amount of isoxyl in the lower stage, which 
contains particles (< 6.4 µm aerodynamic diameter); the fine particle fraction (FPF) is the 
ratio of the FPD to RD; the percent recovery is the ratio of RD to the expected dose; the 
dispersibility is the ratio of FPD to ED; and the percent emission is the ratio of ED to RD.91 
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3.4 RESULTS 
3.4.1 Particle Size Distribution and Morphology 
1) Particles Precipitated from the Injection Method: As shown in Figure 1 and 
Table 2, the commercial isoxyl powder consisted of either large needle-shaped agglomerates 
(lot # 130365-149120) or extremely long needle-shaped particles (lot # 165311-167669) with 
heterogeneous distributions. Depending on different lots, these particles may form 
agglomerates with diameters up to a few hundred microns. When isoxyl was precipitated by 
the injection method from the mixture of VRSA of 1:1, the particles were needle-shaped with 
count median diameter (CMD) of 3.3 µm in width and were more loosely aggregated 
compared to commercial isoxyl. The antisolvent precipitation when VRSA was equal to 1:2 
generated both flake-shaped and needle-shaped particles. A VRSA value of 1:5 yielded 
elongated particles with a shortest dimension of 220 nm [Figure 7 and Table 9].  
 
Figure 7. SEM photomicrographs of (A) commercial isoxyl (lot # 130365-149120) at 50× 
magnification, (B) commercial isoxyl (lot # 130365-149120) at 1400× magnification, (C) 
commercial isoxyl (lot # 165311-167669) at 100×magnification, and the isoxyl particles from 
antisolvent precipitation by injection method: (D) VRSA=1:1 at 700× magnification, (E) 
VRSA=1:2 at 700× magnification, and (F) VRSA=1:5 at 15000× magnification.  
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Table 9. The count median diameter (CMD) of the shortest dimension and the geometric 
standard deviation (GSD) of the elongated isoxyl particles in each powder. 
 Unprocessed 
(lot # 130365-
149120) 
Unprocessed 
(lot # 165311-
167669) 
VRSA=
1:1 
VRSA=
1:2 
VRSA=
1:5 
CMD (µm) 1.47 3.95 3.30 0.88 0.22 Width 
GSD 1.88 1.57 1.68 2.03 1.55 
CMD (µm) 8.2 178 17.0 N.D. 0.99 Length 
GSD 1.90 2.48 1.91 N.D. 1.66 
 
2) Particles Precipitated from the Nozzle Mixing Method: Depending on organic 
solvents, isoxyl particle size and morphology were different: ethanol generated nanofibers 
(width=385 nm, circularity=0.72); isopropanol and THF produced oblate spherical particles 
(width=275 nm and circularity=0.89 for isopropanol, width=220 nm and circularity=0.87 for 
THF); acetone yielded both nanofibers (width=200 nm, circularity=0.4) and oblate spherical 
nanoparticles (width=285 nm, circularity=0.98) [Figure 8 and Table 10]. Isopropanol was the 
first choice of solvent for further optimization of nanoparticle preparation because they 
produced most homogenous nanoparticles with a diameter <500 nm. 
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Figure 8. SEM micrographs of isoxyl particles precipitated from ethanol (A), isopropanol 
(B), acetone (C), and tetrahydrofuran (THF) (D). The micrographs were taken at 5000× 
magnification.  
 
Table 10. Particle size distributions of isoxyl particles precipitated from various organic 
solvent. 
Acetone 
 Ethanol Isopro- panol THF Nanofiber Oblate Sphere 
Circularity 0.72 0.89 0.87 0.40 0.98 
CMW (nm) 385 275 220 200 285 Width GSD 1.5 1.47 1.76 1.44 1.3 
CML (nm) 1280 495 450 1190 390 Length GSD 1.72 1.61 1.63 1.66 1.5 
*PSD: particle size distribution, CMW: count median width, CML: count median length, 
GSD: geometric standard deviation 
  
3) Spray-dried Particles from the Nozzle Mixing: The modified spray drier produced 
approximately spherical particles with count median diameters (Feret’s diameter92) between 
1.19- 1.77 µm in these eight conditions. The average circularity of the microparticles in each 
condition was approximate to unity and these from condition 8 were almost perfect spheres 
B A 
A B 
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[Figure 9A-9H and Table 11]. The particle size distributions, by LD, were unimodal for 
condition 5 to condition 8, bimodal for condition 2 and 4, and multimodal for condition 1 and 
3. Condition 5 to condition 8 resulted in 100% of the particles having diameters < 5µm; 
condition 1 to condition 4 resulted in 70-80% < 5µm [Figure 10]. The yields of the spray 
drying conditions varied from 11.0 to 29.3% [Table 11].  Statistical experimental design and 
analysis showed that isoxyl concentration and nitrogen flow rate were two critical factors 
influencing the yield: an increase in isoxyl concentration and decrease in nitrogen flow rate 
resulted in greater yield. However, statistical analysis could not identify any key factors 
influencing particle size distribution and morphology [Figure 11]. When THF was evaluated 
as a solvent, this produced the undesirable outcome of much larger plate-shaped particles 
with heterodisperse PSD [Figure 9I]. Condition 8 appeared to achieve the desired high yield, 
spherical shape and narrow particle size distribution. 
The addition of mannitol reduced the particle size. When the drug ratio to mannitol is 
1:4.4, the mean count diameter of the isoxyl particles determined by DLS was 455 nm and 
standard deviation was 299 nm [Figure 12A]. However, SEM micrographs showed that these 
isoxyl particles were heterogeneous: some particles were almost spherical while the others 
were elongated [Figure 12B]. Further studies are required to produce nanoparticle aggregates 
with uniform shape and size. 
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Figure 9. SEM photomicrographs of the spray-dried isoxyl particles produced by nozzle 
mixing of isoxyl solutions and water. A-H are the particles from conditions 1-8 respectively 
in Table 1 and I is those from using THF as solvent. The photomicrographs were taken at 
3000× magnification. 
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Figure 10. Particle size distributions of the isoxyl particles measured by laser diffraction 
(LD). A-H represent particles from spray drying condition 1-8. 
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Table 11. Summary of particle size distributions and circularities produced in the eight 
conditions. 
 1 2 3 4 5 6 7 8 
Yield 19.7 29.3 11 25 18.2 11.4 20 28.6 
CMD (µm) 1.25 1.24 1.82 1.57 1.33 1.19 1.67 1.77 
GSD 2.01 1.58 1.75 1.34 1.21 1.26 1.47 1.48 
SEM 
Circularity 0.95 0.93 0.91 0.95 0.91 0.95 0.95 0.98 
Dv,10 (µm) 1.88 1.84 1.98 1.81 1.54 1.86 1.77 1.81 
Dv,50 (µm) 2.20 2.16 2.44 2.13 1.81 2.09 2.02 2.14 
Dv,90 (µm) 6.43 5.78 7.09 6.05 2.36 2.32 2.28 2.67 
LD 
Span 2.06 1.82 2.09 1.98 0.45 0.22 0.26 0.4 
 
*PSD: particle size distribution, CMD: count median diameter, GSD: geometric standard 
deviation, Circularity: 4π(Area/Perimeter2), Dv,10: particle size at 10th percentile of the 
cumulative distribution, Dv,50: particle size at 50th percentile of the cumulative 
distribution, Dv,90: particle size at 90th percentile of the cumulative distribution, Span: 
(Dv,90 -Dv,10)/ Dv,50 
 
3.4.2 Thermal Properties 
At a scanning rate of 40 oC /min, the DSC thermogram of unprocessed isoxyl powder 
showed two peaks at 95.8 oC and 149.7 oC (∆H=98.6 J/g) which corresponded to the boiling 
point of residual ethanol and melting point of isoxyl crystal form I respectively. Both two 
batches (lot # 130365-149120 and lot # 165311-167669) of unprocessed isoxyl powders 
contain the same crystal form of the drug. Isoxyl microparticles from anti-solvent 
precipitation and consequent spray drying exhibited only one peak at 143.5 oC (∆H=76.3 J/g) 
corresponding to crystal form II [Figure 13A]. This may be explained by the processing 
conditions removing residual ethanol and converting isoxyl from form I to form II. For the 
scanning rate of 5 oC /min, the DSC thermogram revealed the same results except that the 
peaks of crystal form I, II and ethanol shifted to 140.5 oC, 136.2 oC and 80.2 oC [Figure 13B]. 
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3.4.3 Fine Particle Fraction and Emitted Dose 
1)Particles Precipitated from the Injection Method: The isoxyl particles, which were 
prepared by injecting isoxyl solution into water and sequentially lyophilizing, exhibited good 
emitted dose performance of 74.9 -76.0% and FPF of 8.8- 12.6% [Table 12]. 
2) Spray-dried Particles from the Nozzle Mixing: The aerodynamic particle size of the 
isoxyl microparticles produced in condition 8 was determined. The powder had an emitted 
dose of 94% and a low FPF of 5.4%. Therefore, cohesive forces of isoxyl microparticles 
were too high to achieve efficient de-aggregation during aerosol dispersion. Addition of 
lactose carrier increased FPF of the isoxyl particles to 8.4% [Table 13].  
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Figure 11. Half normal plot of effects of processing parameters on CMD (A), GSD (B), 
circularity (C), and yield (D) of spray-dried isoxyl particles. In the selected range, only yield 
was influenced by the processing parameters, N2 flow rate (P=0.0025), and isoxyl 
concentration (P=0.0005). (E) represents square plot of effect of these two parameters on 
yield. 
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Figure 12. PSD (A) and SEM (B) of the spray dried isoxyl particles produced by addition of 
mannitol (isoxyl: mannitol=1:4.4).   
 
 
Figure 13. DSC thermograms of commercial isoxyl (gray) and isoxyl microparticles (black) 
prepared by spray drying using condition 8 (isopropanol feed rate 0.7 ml/min, water feed rate 
0.7 ml/min, isoxyl concentration 5 mg/ml, inlet temperature 100 oC, atomization pressure 3 
bar, nitrogen flow rate 600 L/min and aspirator rate 90% of maximum flow). The scanning 
rates were 40 oC/min (A) and 5 oC/min (B). 
 
Table 12. The deposition profile of each commercial isoxyl and isoxyl particles precipitated 
from the injection method. (n=3) 
  Unprocessed VRSA=1:1 VRSA=1:2 VRSA=1:5 
FPF (%) 6.94±2.34 8.76±2.61 12.57±3.35 9.23±1.65 
Dispersibility (%) 8.84±3.32 10.52±4.20 16.63±3.97 12.26±2.90 
Percent Emission (%) 78.46±2.97 74.90±6.44 75.43±5.74 76.03±5.20 
Percent Recovery (%)  103.08±2.43 93.43±0.64 94.52±4.53 101.76±2.76 
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Table 13. The deposition profile of isoxyl microparticles in condition 8 (isopropanol feed 
rate 0.7 ml/min, water feed rate 0.7 ml/min, isoxyl concentration 5 mg/ml, inlet 
temperature 100 oC, atomization pressure 3 bar, nitrogen flow rate 600 L/min and 
aspirator rate 90% of maximum flow). (n=3) 
 Microparticles w/o 
Lactose 
Microparticles w/ 
Lactose 
FPF (%) 5.4 ± 1.7 8.4 ± 1.6 
Dispersibility (%) 5.8 ± 1.9 8.7 ± 1.7 
Percent Emission (%) 94.2 ± 2.3 96.6 ± 0.2 
Percent Recovery (%) 91.1 ± 3.1 97.4 ± 1.8 
 
3.5 DISCUSSION AND FUTURE STUDIES 
      The commercial isoxyl consisted of either large fiber agglomerates or long fibers 
several hundred micrometers in length. Although the sizes of these fibers exceed the 
respiratory range, they could be inhaled, due to their unique aerodynamic properties, as 
indicated by FPF of 6.9%. The main reason is that aerodynamic diameters of the fibers are 
predominantly a function of their cross-section area diameter, or diameter of the smallest 
dimension. Despite relatively high delivery efficiency, these fibers are not suitable for 
inhalation therapy: It has been well established that toxicity of certain fibers depends on 
particle dimension and biopersistence instead of chemical properties. It was reported that 
occurrence of pleural sarcoma was high in rats when the fibers were more than 4 µm long.93 
One mechanism of fiber carcinogenesis is due to cell transformation. After these long fibers 
were phagocytized, they persist in the perinuclear region of macrophages and induce 
chromosomal mutations and consequently cell transformation.94 Also, persistence of fibers in 
the lungs can cause cancer and fibrosis. Macrophages cannot take up fibers much longer than 
their cell dimension. Phagocytosis was incomplete when the rat alveolar macrophages were 
exposed to fiber of 17 µm in length.95 The cut-off length of fibers causing frustrated 
phagocytosis by human alveolar macrophages was expected to be longer than 20 µm, 
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because alveolar macrophages in human (diameter: ~18 µm) are larger than rats (diameter: 
~13 µm). 96 Incomplete phagocytosis leads to persisting of these insoluble fibers in the lungs. 
As shown in results, commercial isoxyl particles are so long that can be potentially persistent 
in the lungs and cause toxic effects. In the study, antisolvent precipitation was used to 
prepare isoxyl particles suitable for the lung delivery.  
By simply injecting isoxyl solution into aqueous phase, the drug was precipitated out as 
needle-shaped particles. It was found that volume ratio of solvent to antisolvent (VRSA) was 
a critical factor controlling particle size. Keeping other parameters consistent, isoxyl particle 
size decreased from the micron to the nano range as the VRSAs were changed from 1:1 to 
1:5. This is explained by increase in local supersaturation ratio (S) and retardance in particle 
growth kinetics. 97 Here, the local supersaturation is defined by the ratio of local drug 
concentration to the equilibrium solubility of drug in the mixture of solvent-antisolvent. After 
isoxyl ethanol solution was injected to water, solubility of the drug decreased much more in 
16% ethanol (VRSA=1:5) than that in 50% ethanol (VRSA=1:1). This led to higher local 
supersaturation ratio in 16% ethanol and consequentially smaller nuclei. However, isoxyl 
nuclei were in a more dilute environment in 16% ethanol compared to 50%, which slowed 
down crystal growth. As a result, when VRSA was equal to 1:5, isoxyl particles were the 
smallest. In addition, the width of these particles was about 200 nm. This increased surface 
area dramatically in comparison to microsphere of the same volume, which can, in turn, 
reduce the residence time of particles in the lungs through rapid dissolution in the lung lining 
fluid.  However, dissolution rate of isoxyl needs to be determined and in-vivo exposure study 
of isoxyl following pulmonary delivery remains to be performed to see whether the rapid 
dissolution is sufficient to achieve therapeutic isoxyl concentration systematically. If that is 
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not true, microparticle targeting to the infected cells may be advantageous with respect to the 
rapid dissolution of nanoparticles and, subsequent, elimination of drug from the lungs before 
tissue penetration for therapy can occur.  
The nozzle mixing method was used to achieve uniform mixing that was hard to obtain by 
the manual injection method. The appropriate solvent was screened when adopting a VRSA 
of 1:5. Four organic solvents, ethanol, isopropanol, acetone and tetrahydrofuran (THF), were 
selected due to their low toxicity in trace quantities. As expected, physico-chemical 
properties of solvents were a key factor controlling particle size and crystal habit. One 
explanation for this observation is the difference between these solvents in degree of 
miscibility with water, a function of supersaturation. Better miscibility resulted in higher 
supersaturation and smaller particle size. Also, it has been reported that an increase in 
supersaturation tends to form elongated particles. 98 This may explain the greater production 
of elongated particles from ethanol or acetone than isopropanol or THF, because isopropanol 
is more hydrophobic than ethanol and acetone is completely miscible with water but THF is 
not. However, the effect of solvent can be complicated by other properties such as hydrogen 
bonding, dipole moment, dielectric constant, which facilitate crystal growth predominately in 
one dimension.89 Isopropanol delivered the best product, oblate spherical nanoparticles <500 
nm in length with most homogeneous distribution.  
The precipitating particles can be simultaneously spray dried. The initial aim was to collect 
the precipitating nanoparticle in the form of aggregates. The preparation of isoxyl particles in 
the study consisted of two processes, antisolvent precipitation and simultaneous spray drying, 
which were controlled by seven main factors, type of solvent, organic feed rate, water feed 
rate, inlet temperature, drug concentration, nitrogen pressure and flow rate. Effects of these 
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factors on particle size were evaluated in a statistically designed experiment. However, isoxyl 
nanoparticle aggregates could not be obtained by simply varying these operating conditions 
since nano-sized precipitates agglomerate into microparticles in the process. It appeared that 
primary sizes of the particles were determined by amount of isoxyl in the atomized droplets 
independent of the precipitate size. Therefore, the median diameter of the spray-dried isoxyl 
particles can be predicted by the equation 5 99:  
                                                     3
particles
dropletparticle
Cdd ρ=                                          [5] 
Here dparticle and ddroplet are the spray-dried particle diameter and the atomized droplet 
diameter. C is the concentration of isoxyl in the mixture of solvent and antisolvent and ρparticle 
is density of the particle. According to the information from the manufacturer (Buchi 
Labortechnik AG, Flawil, Switzerland), median volume diameters of the atomized aqueous 
droplets should be 10.48 µm when nitrogen flow rate is 830 L/h and 30.6 µm when nitrogen 
flow rate is 440 L/h. Assuming the median volume diameter of the atomized droplets is 
around 20 µm for 600 L//h and density of isoxyl is close to 1 µg/ml, the median diameter of 
resulting isoxyl particles is predicted to be between 0.92 to 2.7 µm, which is consistent with 
the experimental results. This also explains the production of larger microparticles when 
THF was used as solvent. Isoxyl has a higher solubility in THF than alcohols. Theoretically, 
during antisolvent precipitation process, smaller particles should precipitate due to an 
increasing local supersaturation. However, the result showed that final particle size of the 
spray-dried particles from THF was much larger than those from alcohols because a higher 
concentration of isoxyl was present in one atomized droplet during spray drying.  
The spray drying method failed to produce isoxyl nanoparticle aggregates due to 
irreversible agglomeration which commonly occurs. The isoxyl nanoparticles can only exist 
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as separate particles in a dilute suspension. In order to conduct in-vivo disposition and 
efficacy studies, this diluted nanoparticle suspension can be made immediately prior to 
delivery by nebulizer. The spray-dried nanoparticle aggregates may be prepared by using 
appropriate surfactants and/or bulking agents. Theoretically, appropriate stabilizers can slow 
growth of the particles by condensation and coagulation, which reduces particle sizes. 
Stabilizers and bulking agents can also cover the precipitating particles and prevent them 
from agglomerating in the drying process and during a long-term storage. The bulking agent, 
mannitol, was evaluated in the study. Nanoparticle aggregates were produced but these 
particles were heterodisperse. Therefore, either mannitol itself or the amount of mannitol was 
not sufficient to prevent nanoparticle agglomeration. Further studies are needed to screen 
suitable surfactants or bulking agents for isoxyl nanoparticle preparation. The choice of 
surfactants and bulking agents are very limited for pulmonary delivery.  Sodium oleate, 
sodium stearate, cetyl alchohol, tyloxapol, pluronics, lactose, mannitol, polyvinyl alcohol 
(PVA), polyethylene glycol (PEG), hydroxylpropylmethylcellulose (HPMC), may be 
considered, although not all of these are present in approved products. Some of them are 
present in FDA-approved inhalation products, while some of them have been studied 
extensively and are generally recognized as safe. Theoretically, 30-40% w/w of these 
stabilizing agents is required to keep nanoparticles with diameters between 120 to 300 nm 
separate.100  
The crystalline/amorphous states influence many physicochemical properties of drugs 
such as saturation solubility, moisture sorption, particle stability.83, 101 Isoxyl is known to 
exist in two different crystal forms. The needle crystals by crystallization from ethanol have 
higher melting point of 149 oC (∆H=98 J/g) and lower aqueous solubility of 0.88 µg/ml than 
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these from hexane that have melting point of 141 oC (∆H=77 J/g) and aqueous solubility of 
17.8 µg/mL.102 During synthesis, isoxyl was purified by crystallization of the drug from 
ethanol. 103 As expected, DSC profiles showed that the commercial isoxyl powder contains 
crystal form I and a large quantity of residual ethanol. In comparison, microparticle 
processing improved properties of isoxyl in the following ways: 1) Spray drying completely 
removed the residual ethanol; 2) conversion of isoxyl crystal form I to form II occurred. 
These phenomena contributed to expectations of much higher solubility. However, it remains 
to be established whether polymorph conversion occurred during precipitation from 
isopropanol/water or spray drying.  
The needle-shaped isoxyl particles generated from the injection method and 
lyophilization exhibited higher fine particle fraction and lower emitted dose than those 
spherical particles from the nozzle mixing and spray drying. Theoretically, particle shape 
greatly impacts on their dispersion and aerodynamic behavior.92, 104 Inspiratory flow fluidizes 
and deaggregates particles delivered for the Inhalator®, a passive dry powder inhaler. 
Dispersion of particles requires several processes: dilation, flow, fluidization and 
deaggregation. The interparticulate interaction between elongated particles is very unstable. 
After the elongated particles are dispersed, most of them line up along air streams. As a result, 
their aerodynamic diameters only depend on their shortest dimension and independent of 
their length. Particles that are inhaled to the respiratory tract will travel further and achieve 
better deposition in the deep lung than the spherical particles with the same geometric 
diameters.91, 92, 104-106 Consequently, the elongated particles achieved high fine particle 
fraction due to apparently good dispersion and aerodynamic properties. However, the flow 
property of needle-shaped particles is worse than spherical particle. This caused that more 
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particles were adhered to the wall of capsule inside the device and resulted in lower emitted 
dose. The spray-dried isoxyl microparticles were delivered following blending with carrier 
lactose, which increased FPF from 5.4 to 8.4%. Further work is required to improve the 
performance of lactose blends with isoxyl. 
   
3.6 CONCLUSION 
Antisolvent precipitation in water was used to prepare isoxyl particles suitable for 
lung delivery. Nanoparticles with a count median width (CMW) of 275 nm and a count 
median length (CML) of 495 nm were produced using isopropanol as a solvent and a VRSA 
equal to 1:5. Spray drying failed to produce nanoparticles or their aggregates in dry form, but 
generated near spherical microparticles with a count median diameter (CMD) of 1-2 µm. 
Addition of mannitol in antisolvent at a drug to mannitol ration of 1:4.4 during processing 
produced isoxyl nanoparticle aggegregates. A range of microparticle and nanoparticle 
preparations have been evaluated. Further work on their delivery as aerosols is required to 
assess the potential for inhaled treatment of tuberculosis. 
  
 
 
 
Chapter 4 
 In-vitro Cytotoxicity and Potency of Isoxyl Particles 
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4.1 INTRODUCTION 
Isoxyl was believed to be a bacteriostatic agent. When tubercle bacilli were exposed to 
isoxyl at a concentration of 10 µg/ml for 4 days, the viable counts of bacilli decreased but 
started increasing after removal of the drug.12 For bacteriostatic agents, they usually kill 
virulent microorganisms with the help of immune system.  
Drug efficacy has been demonstrated in animal studies. Crowle et al. delivered three 
different doses of isoxyl in corn oil, 62.5 mg/kg, 125 mg/kg or 250 mg/kg, to the infected 
mouse to test dose-dependent drug effectiveness. A dose > 62.5 mg/kg protected the mouse 
against tuberculosis which was indicated by suppression of the increase in lung density.81 As 
shown in chapter 1, addition of isoxyl to capreomycin, rifampicin, and ethambutol 
dramatically increased the survival rate of rabbits infected with M. bovis.20  Konopka et al 
administered isoxyl to the infected guinea pigs and measured extent of disease in the lungs, 
liver and spleen by histopathologic studies. In comparison to controls, isoxyl demonstrated 
considerable antituberculosis activity.82 However, the clinical trials performed in 1960s and 
1970s showed that isoxyl had modest effect in monotherapy and combination therapy as 
shown in Table 14. Some clinical results were even contradictory. Stahle found that isoxyl 
clearly had good antituberculosis effect which was not significantly inferior to isoniazid 
(INH).18 However, Olejnicek et al came to the conclusion that combination therapy of isoxyl 
and isoniazid was not better than monotherapy of isoniazid in advanced pulmonary 
tuberculosis based on number of patients who had a conversion of sputum and degree of 
INH-resistance development.107  
Isoxyl has been reported to be non-toxic. When the drug was given to rats by the oral 
route at a daily dose up to 14 g/kg, much higher than therapeutic dose (50-100 mg/kg), for 
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1.5 years, it showed no effects on food consumption, reproduction potential, growth, renal 
and hepatic function, and hematopoietic systems, and it is not teratogenic, embryotoxic, and 
carcinogenic. The high dose only caused a slight increase in the weight of liver, level of 
alkaline phosphatases, and transitory increase in the weight of the thyroid gland, but no 
biological dysfunctions were detected.18, 108 
Due to extremely low bioavailability of isoxyl, the previous in-vivo efficacy and toxicity 
studies of the drug deserve further investigation using in-vitro cell models, which allows for 
higher and more accurate dosing. Especially after a large dose of isoxyl is delivered directly 
to the lungs, most of the drug may target macrophages in the lungs. Further investigation is 
needed to assess the cytotoxicity and efficacy of the drug when administered to macrophages 
alone or coinfected with mycobacteria at higher concentration. This will help to determine 
the therapeutic window of the drug delivered as an aerosol. However, studies of efficacy and 
cytotoxicity of isoxyl using macrophages are rare. Phetsuksiri et al reported an in-vitro 
efficacy study of isoxyl using murine bone marrow macrophages and showed a dose-
dependent bactericidal activities and killed intracellular bacilli with a 4-log-unit reduction at 
a concentration of 2.5 µg/ml. The Alamar Blue assay showed that isoxyl was not toxic at up 
to 2.0 µg/ml in isolated murine bone marrow macrophages. 13 In this study, differentiated 
THP-1 cells were employed as a macrophage model to evaluate potential of the isoxyl 
particles with different particle characteristics to be effective agents to eliminate intracellular 
TB without killing healthy macrophages. 
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Table 14. Summary of clinical results of isoxyl (table was modified from reference 24 and 
data from references 20, 109, 115 were added.) 
Treatment 
(Daily Dose) 
Time of 
Therapy 
(month) 
Negative on 
Culture 
X-ray 
improvement
Develop-
ment of 
Resistance 
(drug) 
Source 
Isoxyl (6 g) 1.5-4.5 47% (15/32) 34% (11/32) N.D. Heidelbach et al.109 
Isoxyl (10 g) > 6 20% (4/20) 15% (3/20) N.D. Titscher110 
Isoxyl (20 g) 3 45% (14/31) 84% (26/31) N.D. Dormer111 
Isoxyl (6 g) 3-5 27% (4/15) 29% (6/21) N.D. Boszormenyi21 
Isoxyl (6 g) plus 
INH (5 mg/kg) 3 ND 21% (4/19) N.D. 
Boszormenyi
21 
Isoxyl (6 g) plus 
INH (300 mg) 4 89% (34/38) 69% (22/32) 1 
Hekking et 
al22 
Isoxyl (6 g), 
INH (600 mg) 4 89% (32/38) 48% (15/31) N.D. 
Favez et 
al.112 
Isoxyl (6 g), 
INH (10 mg/kg) 6 75% (15/20) 46% (6/13) 15% (INH) 
Aksugur et 
al.113 
Isoxyl (6 g), 
INH (300 mg) 6 38% (5/13)  69% (INH) 
OLejnicek et 
al.107 
Isoxyl (6 g), 
INH (5 mg/kg) 6 63% (17/27) 60% (16/27) 26% (INH) Tousek
24 
Isoxyl (4 g), 
INH (200 mg) 6 40% (16/40) 95% (38/40) 
10% 
(Isoxyl) 
50% (INH) 
Moodie. et 
al114 
Isoxyl (4 g), 
SM (1 g), INH 
(200 mg) 
6 83% (92/111) 60% (65/109) 
8% (INH) 
8% (SM) Kass
115 
Isoxyl (5 g), 
PAS (12 g) 6 50% (18/36)  
8% (Isoxyl) 
3% (PAS) Eule et al
116 
Isoxyl (6 g), 
INH (5 mg/kg), 
SM (1 g) 
3-4 
3 months: 
86.5% 
(16/22) 
4 months: 
100% 
(22/22) 
4 months: 
72.5% 0 Nickling
117 
p-aminosalicylic acid (PAS), Pyrazinamide (PZA), INH: isoniazid, N.D.: not determined 
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4.2 RATIONALE AND EXPERIMENTAL DESIGN 
THP-1 cells can be differentiated by PMA to macrophage-like cells. Factors including 
particle sizes, shapes, and composition can affect phagocytic activities of macrophages. 118 
Spray-dried microparticles may be taken up effectively by macrophages while isoxyl 
solutions (controls) will transport isoxyl molecules through cell membrane. Since isoxyl is 
poorly soluble, controls were prepared by diluting concentrated isoxyl solution in dimethyl 
sulfoxide (DMSO) with cell culture media. It has been shown that DMSO < 2% would not 
kill mycobacteria. 13 Therefore, the final concentration of DMSO was 1% in the study. Isoxyl 
precipitates out to form particles during mixing isoxyl solution in DMSO at high 
concentrations with cell culture media. This will complicate the comparison between isoxyl 
microparticles and the controls. However, since characteristics of these precipitates from 
DMSO may be different from the spray-dried microparticles, this can lead to change in 
disposition of isoxyl in macrophages. Higher uptake of drug into macrophages may 
simultaneously increase killing of intracellular bacilli and deserves further investigation. 
Comparison between the spray-dried microparticles and controls of nanoparticles/molecules 
in 1% DMSO in terms of disposition, toxicity and efficacy may shed a light on this issue.  In 
the present study, BCG, a model mycobacterium, was used to infect PMA-differentiated 
THP-1 cells.  The infected cells were exposed to isoxyl microparticles suspensions and 
soluble/nanoparticle controls at a series of concentrations from 0.5 to 100 µg/ml, which were 
determined by the Minimum Inhibitory Concentration (MIC) reported previously. Dose-
dependent and preparation-dependent effect on drug efficacy and toxicity were evaluated in-
vitro. 
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4.3 MATERIALS AND METHODS 
4.3.1 Materials 
DifcoTM Middlebrook 7H10 agar and DifcoTM Middlebrook 7H9 were purchased 
from BD. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) and phorbol 
myristrate acetate (PMA) were purchased from Sigma. Triton X-100 was obtained from 
Fluka. Formalin (10%, Certified buffer), anhydrous isopropanol and the eight-well Lab-
TekTM II Chamber SlideTM Systems were purchased from Fisher Scientific. 10X ADS was 
made from 5% BSA, 0.2% dextrose and 0.81% NaCl. 7AGT media were prepared by 0.47% 
DifcoTM Middlebrook 7H9, 0.5% Glycerol, 0.05% Tween 80 and 1X ADS. 
 
4.3.2 Cell Culture and Bacteria Strains 
THP-1 cells were purchased from American Type Culture Collection (ATCC) and 
grown in complete RPMI 1640 media (Cellgro) supplemented with 10% heat inactivated 
fetal bovine serum (Atlanta), 10 mM HEPES (cellgro), 1.0 mM sodium pyruvate (Gibco), 
0.05 mM 2-mercaptoethanol (Gibco), 1X MEM non-Essential Amino Acids (Gibco).THP-1 
cells were seeded on 98-well plate and differentiated into macrophage-like cells by treating 
with 50 ng/ml of PMA for 48 h, followed by washing with incomplete RPMI media (without 
FBS) three times to remove PMA. Mycobacterium bovis, Bacille Calmette-Guerin (BCG) 
was from Organon Teknika Corp, Durham, NC. BCG was grown in 7AGT media until 
OD600nm reached log phase. 
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4.3.3 Preparation of Isoxyl Suspensions and Solutions  
Isoxyl microparticles (condition 8) were prepared by antisolvent precipitation and 
simultaneous spray drying as described in Chapter 3. Isoxyl microparticles were accurately 
weighed and then suspended in complete RPMI media to make a concentration of 100 µg/ml. 
Concentrations of 0.5, 1, 2.5, 5, 10, 50 µg/ml were prepared by a serial dilution with 
complete RPMI 1640 media. As controls, isoxyl was dissolved in DMSO at concentrations of 
0.05, 0.1, 0.25, 0.5, 1, 5, 10 mg/ml and then diluted by 100-fold with RPMI 1640 media. This 
resulted in the same mass drug concentrations as those of microparticles and DMSO solution 
with a final concentration of 1%. The spray-dried isoxyl microparticles suspended in 1% DMSO 
and isoxyl in 0.5 and 2% DMSO were also made as described above to study the effect of 
DMSO on drug penetration. Particles size of isoxyl precipitates made by mixing DMSO with 
media in the controls, were measured by DLS (Nicomp particle sizing systems, AutodilutePAT 
Model 370 Santa Barbara, CA). 
 
4.3.4 Minimum Inhibitory Concentration (MIC) determination 
The agar plate dilution method was used to determine MIC of isoxyl, which was 
defined as the lowest drug concentration that inhibited colony growth on the agar plates. 
Agar plates were prepared with DifcoTM middlebrook 7H10 containing 1X ADS, 0.5% 
glycerol and a series of concentrations of isoxyl (0, 0.1, 0.5, 1, 2.5, 5, 10 µg/ml).  A BCG 
suspension (2.2 × 105 cells/ml) was prepared. Three 10-fold dilutions of the suspension (10-1, 
10-2, 10-3) of 100 µl were plated on isoxyl-containing and isoxyl-free agar plates. The colony-
forming units (CFUs) were counted 4 weeks after incubation of agar plates at 37 oC. 
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4.3.5 Cell Viability Assays 
After the THP-1 cells were exposed to isoxyl microparticle suspensions or isoxyl in 1% 
DMSO in cell culture medium, the viability of these cells were assessed by their ability to 
reduce yellow MTT to purple formazan or level of LDH (lactose dehydrogenase) released to 
the cell culture media. Negative controls consisted of cells without exposure to isoxyl. The 
cell supernatants were collected and used to measure activities of LDH by using the 
commercially available kit from Sigma. Fresh media without phenol red and FBS of 100 µl 
and MTT (5 g/ml) of 10 µl were added to each well and the plates were incubated for 3.5 h. 
MTT solubilization solution (10% triton X-100, 0.1 N HCl in anhydrous isopropanol) of 100 
µl was added to each well. The plates were then incubated overnight at 37 oC incubator to 
completely dissolve formazan crystals. Absorbance was measured by using Bio-Rad Model 
3550 microplate reader (Bio-Rad Laboratories, Hercules, CA) at a wavelength of 570 nm and 
background absorbance at 690 nm.  
 
4.3.6 Preliminary Efficacy Studies 
The PMA-differentiated THP-1 cells were cultured in the eight-well Lab-TekTM II 
Chamber SlideTM Systems at a concentration of 2×105 cells/well. BCG, which reached mid-
exponential growth phase, was diluted in complete RPMI media and then added to the cell 
monolayer at a Multiplicity of Infection (MOI) of 1. After incubation at 37 oC for 4 h, the 
supernatants were discarded and the cells were washed with RPMI media three times to 
remove the intercellular bacteria. One slide was used to determine the initial infection at Day 
0. Three wells of the slide were lysed with buffer (0.05% sodium dodecyl sulfate in PBS). 
Cell lysates were diluted three times (10-1, 10-2, 10-3) and 111 µl of the dilutions were spread 
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on drug-free M7H10 agar plates. The supernatants were discarded and the slide was saved in 
10% Formalin until analysis. For the rest slides, the BCG-infected THP-1 cells were exposed 
to a series of concentrations of isoxyl microparticles suspensions or controls of isoxyl in 1% 
DMSO or 1% DMSO (vehicle control) or blank media (untreated control). After 5-days of 
incubation at 37 oC, three wells of each slide were washed once by RPMI media, lysed by 
buffer (SDS 0.05% in PBS) and then plated. The colony-forming units (CFUs) of BCG were 
counted 4 weeks after incubation. The slides were saved in 10% Formalin until analysis. 
Slides stored in Formalin were washed, stained with auramine-rhodamine and visualized by 
microscopy to count the number of cells and intracellular bacilli.  
 
4.4 RESULTS 
4.4.1 Characterization of Isoxyl Particles in the Suspensions 
As described in Chapter 3, microparticles produced by antisolvent precipitation and spray 
drying were approximately spherical and 1.77 µm in count median diameter, determined by 
microscopy. For the controls, nanoparticles with an intensity-weighted mean diameter of 
100-200 nm, from photon correlation spectroscopy, were produced when isoxyl, at 
concentrations of 5 and 10 mg/ml, was mixed with cell culture media at a ratio of 1:100. The 
solubility of isoxyl in cell media containing 1% DMSO was ~2 µg/ml [Unpublished data]. 
Therefore, for isoxyl in 1% DMSO of 5 and 10 µg/ml, nanoparticles may be produced but the 
concentrations were too low to be detected by DLS. The forms of isoxyl available in 1% 
DMSO at various concentrations were listed in Table 15. 
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          Table 15. The form of isoxyl available in 1% DMSO at various concentrations. 
Conc. (µg/ml) 100 50 10 5 2.5 1 0.5 
Dominant Form NP NP N.D. N.D. M M M 
NP: nanoparticles which were detected by DLS, N.D.: not determined, M: molecule 
 
4.4.2 MIC Determination 
 No visible colony was detected when the isoxyl concentration was > 2.5 µg/ml. The 
CFUs (colony forming units) of the plate containing 1 µg/ml Isoxyl in 1% DMSO were 
comparable to the control containing 1% DMSO [Table 16]. 
 
         Table 16. Colony Forming Units (CFUs) on plates inoculated with BCG cells. 
Isoxyl Conc. (µg/ml) 0 1.0 2.5 5 10 
CFUs 127±38 119±33 0 0 0 
 
4.4.3 Cytotoxicity of Isoxyl Microparticles and Nanoparticles 
Isoxyl microparticles did not show any cytotoxic effect on the THP-1 cells one [Figure 
14A] or five [Figure 15A] days following exposure. More than 90% of the cells were still 
viable when < 500 µg/ml of isoxyl microparticles was tested. In comparison, the cells 
exposed to isoxyl in 1% DMSO at high concentrations (10-100 µg/ml) exhibited larger 
effects on cell viability, as estimated by MTT assay, one day following exposure, which were 
50-70% of control [Figure 14A and 15A]. However, the mitochondrial dehydrogenase 
activity of the THP-1 cells recovered to around 100% of controls two days later [Figure 15A]. 
Positive controls lost most of their mitochondrial dehydrogenase activity (1.4-2.5% of 
control). DMSO is a well-known penetration enhancer and can play a role in the drug 
solution effects at day one. Several controls, isoxyl microparticles in 1% DMSO and isoxyl 
in 0.5-2% DMSO, were included to assess this possibility. Regardless of DMSO 
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concentration it appeared similar trends for a series of isoxyl concentrations, from which it 
was inferred that DMSO has no effect on penetration of the drug into the cells but isoxyl 
particle characteristics were important for uptake [Figure 14C]. 
Dipalmitoylphosphatidylcholine (DPPC), a lung surfactant, was employed to mimic the in-
vivo environment and to aid in microparticle dispersion. As expected, DPPC at 0.05% did not 
affect viability of THP-1 cells, but seemed to activate the metabolic state of THP-1 cells as 
indicated by higher mitochondrial dehydrogenase activities than the controls (around 120%) 
[Figure 14A and 14B].  
Levels of LDH leakage were determined as an indication of challenges to the integrity of 
the cells leading to cytoplasmic enzyme release. All the treatments including 10-100 µg/ml 
isoxyl in 1% DMSO did not release significantly greater LDH then the controls. However, 
the positive control resulted in sudden release of LDH [Figure 15B].  
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Figure 14.  MTT reductions of THP-1 cells after they were exposed to isoxyl for 24 h. (A) 
Isoxyl in 1% DMSO, isoxyl microparticles, and isoxyl microparticles with 0.05% DPPC. (B) 
Controls of 1% DMSO, 0.05% DPPC and 1% Triton. (C) Isoxyl in 0.5%, 1%, 2% DMSO 
and isoxyl microparticles in 1% DMSO. 
 
4.4.4 Preliminary Efficacy Studies 
The bacterial burden expressed in colony forming units (CFUs) of the untreated control 
and 1% DMSO treated cells increased 2.6- and 3.3-fold five days after incubation, but those 
of isoxyl at concentrations of 0.5 to 2.5 µg/ml in 1% DMSO were unchanged. This may be 
explained by isoxyl being bacteriostatic at concentration between 0.5 to 2.5 µg/ml. When the 
drug concentration increased to 5 µg/ml, a 3.9-fold reduction in bacterial count was observed 
in comparison to Day 0 and a 10.3-fold reduction in comparison to untreated control [Figure 
16A]. The microscopy study also revealed antituberculosis effect of isoxyl [Figure 17]. For 
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isoxyl microparticles suspended in cell culture media, concentrations > 5 µg/ml showed 
bactericidal activity. When isoxyl microparticle concentration was equal to 5 µg/ml, bacterial 
count reduced by 2.8-fold in comparison to Day 0 [Figure 16B].  
Figure 15. (A) The effect of isoxyl in 1% DMSO or isoxyl microparticles at a series of 
concentrations on THP-1 cells determined by (A) MTT assays and (B) LDH assays. 
 
Figure 16. In-vitro efficacy of isoxyl in 1% DMSO (A) and isoxyl microparticles (B) 
determined by CFUs. *Bacterial count of the treatment was statistically different from that of 
Day 0 (P<0.05, Dunnett’s t test was performed). 
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Figure 17. In-vitro Efficacy of Isoxyl in 1% DMSO. A1-G1 were taken by phase contrast 
microscopy to show the infected THP-1 cells and A2-G2 were the same areas examined by 
Fluroscein-isothiocyanate (FITC) fluorescent microscopy to exhibit intracellular BCG. 
(A1) and (A2): Day 0; (B1) and (B2): Control (no treatment, day 5); (C1) and (C2): Control 
(1% DMSO, day 5); (D1) and (D2): Isoxyl (0.5 µg/ml, day 5); (E1) and (E2): Isoxyl (1 
µg/ml, day 5); (F1) and (F2): Isoxyl (2.5 µg/ml, day 5); (G1) and (G2): Isoxyl (5 µg/ml, day 
5).  
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4.5 DISCUSSION 
The poor solubility of isoxyl limits its use as a therapeutic agent for treatment of MDR 
strains of tuberculosis following oral route of administration. Isoxyl microparticles, 1-2 µm 
in median diameter, which may be delivered as aerosols from a dry power inhaler (DPI) 
directly to the lungs of infected patients, can be prepared by antisolvent precipitation and 
simultaneous spray drying as described in Chapter 3.119 Direct delivery of these particles to 
the lungs will not only result in high local concentrations but may also target alveolar 
macrophages, the host cells of TB bacilli. It has been reported that particles with diameters of 
500 nm to 3µm are efficiently phagocytized when these particles encounter alveolar 
macrophages.42-44, 51 Also, phagocytosis of hydrophobic nanoparticles decreases with 
decreasing size.45 Therefore, isoxyl microparticles, nanoparticles and solubilized drug 
(molecules) would be expected to penetrate different sites in the lungs.  
Two cytotoxicity studies were performed. MTT assays measured the mitochondrial 
dehydrogenase activity of viable cells. Interference with the enzyme or cell death decreases 
the activity of the dehydrogenase as indicated by reduction of methylthiazol tetrazolium 
(MTT) to coloured formazam. This phenomenon was seen after THP-1 cells were exposed to 
isoxyl nanoparticles which were produced by mixing the drug solution in DMSO with cell 
culture media for one day. However, the enzyme activity recovered after the cells exposed to 
the nanoparticles for an extended period of time. This implied the isoxyl nanoparticles 
interfered with activity of the mitochondrial dehydrogenase, but the effect was tolerated by 
the viable cells subsequently. Lactose dehydrogenase (LDH) bioassays also showed that 
isoxyl, in any form, did not kill the cells. LDH is a stable cytoplasmic enzyme. For a certain 
culture conditions, the LDH release per cell is constant, but lysis of the cells increases LDH 
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leakage. When the cells were treated with isoxyl nanoparticles and microparticles at the 
concentrations < 100 µg/ml, LDH level were equivalent to untreated control. In contrast, 
positive controls had 4-fold increase in LDH leakage in comparison to the untreated controls. 
The isoxyl in either form did not impair the integrity of the cells as estimated by LDH release. 
This is further indication that isoxyl microparticles and nanoparticles were not cytotoxic. 
The results of the MTT assay suggest that isoxyl interferes with the enzyme to a greater 
extent when delivered as nanoparticles compared to microparticles but it is not clear that this 
results in loss of viability. This seems to conflict with the previous reports where 
microparticles appear to be more effectively phagocytized by macrophages than 
nanoparticles.  However, this is not surprising, because phagocytosis efficiency is associated 
with not only primary particle size but also other particle characteristics including particle 
aggregation, shape, charge, crystalline structure, surface and dispersion properties. Isoxyl 
microparticles are spherical and contain crystal form II.119 The shape and polymorphism of 
the isoxyl nanoparticles precipitated from DMSO requires investigation. It is known that 
isoxyl can occur in crystal form I if it is precipitated from ethanol.102 Also, dispersion of 
particles in cell culture media can play an important role. Treatment of 50 and 100 µg/ml 
isoxyl microparticles provided ratio of particles to cells about 6:1 and 12:1 respectively. 
However, microscopic examination demonstrated that the isoxyl microparticles formed 
aggregates in the media. These aggregates can constrain uptake to a limited number of cells. 
Large aggregates may avoid macrophage uptake altogether. However, the nanoparticles were 
made freshly in cell culture, so they may attach to macrophages immediately as individual 
particles or form aggregates in microparticle sizes suitable for rapid uptake. Consequently, 
the cells were exposed to higher number concentration of the isoxyl nanoparticles than the 
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microparticles when the mass doses were the same. Therefore, care should be taken when it 
comes to a conclusion that primary particle size is a key factor for macrophage phagocytosis 
before studying particle behavior leading to secondary structures in cell culture media.  
Higher intracellular drug levels delivered by the nanoparticles compared to microparticles 
would be expected to lead to improved efficacy, in treating infected cells. However, this was 
not the case. The preliminary in-vitro studies showed that both isoxyl microparticles and 
isoxyl presented in 1% DMSO had bactericidal activity against intracellular BCG at a 
concentration of 5 µg/ml.  These particles will be employed in future to carry out more in-
vitro efficacy studies and as possible treatment for tuberculosis in an infected guinea pig 
model 120.  
 
4.6 CONCLUSIONS 
Isoxyl > 2.5 µg/ml inhibited growth of BCG completely on agar plates and > 5 µg/ml 
showed bactericidal activity to intracellular BCG. Isoxyl nanoparticles precipitated from 
mixing DMSO with cell culture media may result in the transport of drug more effectively 
into the THP1 phagocytic cells than micropraticles as indicated, indirectly, by MTT assays, 
but this did not produce higher cytotoxicity or efficacy in the infected cell model. Further in-
vitro work is required prior to conducting efficacy studies in animal model of tuberculosis. 
  
 
 
Chapter 5 
Conclusions and Future Studies 
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Tuberculosis remains a serious infectious disease resulting in the death of more than two 
million people annually. Shockingly, the incidence of multiple drug resistance to the first and 
second line agents employed to treat tuberculosis is increasing globally. New drugs are 
desperately needed to respond to this major challenge to public health internationally. 
Assessment of drugs that have previously shown some promise would help in this endeavor.  
Isoxyl is an effective drug to treat MDR tuberculosis (MIC: 1-10 µg/ml for various 
resistant strains). However, the efficacy of the drug has been questioned due to failure of 
some clinical trials. Due to absence of a reliable method to quantify drug concentrations in 
the biological samples, the exact mechanism of poor in-vivo behavior of the drug was not 
elucidated. In specific aim 1 a quantitative analytical method was developed and validated 
for determination of concentrations of isoxyl in plasma following i.v. and oral 
administrations. The drug was extracted with acetonitrile from guinea pig plasma and 
quantified by a Hewlett Packard 1100 series HPLC coupled with a Spherisorb 5µm ODS2 
(2×100 mm) column and UV detection at 270 nm. The mobile phase was 70% ACN in 20 
mM ammonium acetate buffer.  Isoxyl peak was eluted at 4.8 min with no interference with 
the peaks of impurities from plasma and internal standard. According to FDA guidance, the 
HPLC method was sensitive, reproducible, and accurate for quantification of isoxyl in guinea 
pig plasma. The preliminary in-vivo study of isoxyl showed that two different doses of i.v. 
administration resulted in the same pharmacokinetic profiles. This implied that drug 
precipitation might occur near to the site of injection due to poor solubility of the drug. More 
replicates are required to be conducted to confirm the conclusion and to identify the site of 
precipitation. Oral administration of therapeutic dose of isoxyl could not approach minimum 
inhibitory concentration (MIC) in plasma. There are two plausible reasons for this result: 1) 
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Insolubility of the drug resulted in poor dissolution in the gastrointestinal tracts and 
malabsorption; and 2) in comparison to the previous reports that detected much higher drug 
levels in serum using microbiological and radiochemical methods, this suggested that isoxyl 
may be transformed to active metabolites following oral administration. Therefore, either 
poor solubility or highly variable drug metabolism may contribute to unsatisfactory clinical 
outcomes. Delivery of isoxyl to the lungs, a major site of Mycobacterium tuberculosis (MTB) 
infection, may rescue this abandoned drug through increasing local effect.  
To further study the drug levels in plasma, slower infusion of isoxyl to guinea pigs will 
be performed to obtain pharmacokinetic parameters. This experiment may not be necessary if 
isoxyl plasma concentration do not achieve therapeutic levels even after inhalation of the 
drug to the lungs. In this scenario, obtaining high local drug concentration would be the 
primary aim. The drug will be delivered by insufflator or nebulizer to guinea pigs which will 
then be sacrificed at various time points. Isoxyl concentrations in the lungs of these animals 
should be determined. These results will be compared to those from the animals who 
received isoxyl by oral and i.v. administration. If the local drug concentration can not achieve 
the therapeutic range in the lungs by pulmonary delivery of isoxyl, metabolism of the drug 
might be a serious problem. Further investigation of isoxyl metabolism using liver and lung 
microsomes can be carried out to identify the metabolites, and if they are detected, this may 
permit deducing the role of metabolizing enzymes involved in the process. Also, isoxyl can 
be incubated with lung and liver miscrosomes and the metabolites can be isolated for the 
future toxicological and efficacy studies. Study of isoxyl metabolism may allow 
identification of better anti-tuberculosis drug candidates.  
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Specific aim 2 was to optimize particle processing conditions to prepare isoxyl particles 
suitable for pulmonary delivery. Isoxyl particles for pulmonary delivery were prepared by 
anti-solvent precipitation. Nano-fibers with a width of 200 nm were obtained by injecting 
isoxyl solution in ethanol to water at a volume ratio of solvent to antisolvent (VRSA) of 1:5. 
Based on this preliminary result, a well-controlled method, involving nozzle mixing, was 
employed to prepare isoxyl particles. All the particles were 200 to 400 nm in width but had 
different lengths depending on properties of the solvents. However, generating these 
nanoparticles by simultaneous spray drying produced isoxyl microparticles (1.19- 1.77 µm) 
with no discernible nanoparticle substructure. The processing parameters did not have 
significant effect on particle size. The primary reason is that nanoparticles agglomerated 
during the drying process and the final particle size is only dependent on the amount of the 
drug in the atomized droplet. Addition of the bulking agent, mannitol, helped to prevent these 
nanoparticles from agglomeration in the process and resulted in nanoparticle aggregates in 
micron sized superstructures. Future study is necessary to increase homogeneity of the 
nanoparticles by applying appropriate amount of mannitol or other excipients as discussed in 
Chapter 3. Aggregation of the spray-dried microparticles resulted in relatively low fine 
particle fractions. This can be improved by employing different carriers, for example lactose, 
mannitol or trehalose.121-123 Also, modifying morphology and surface of these carriers can 
achieve optimized adhesion forces between drug particles and carriers which allow effective 
separation of microparticles from aggregates during blending and easy detachment of these 
microparticles from carriers after aerosolization.106, 124-132 This may further enhance dry 
powder inhaler (DPI) performance. 
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The previous in-vivo reports of toxicity and efficacy of isoxyl were not reliable due to 
poor absorption of the drug. However, the in-vitro studies of the drug were very scarce. 
Specific aim 3 was to assess cytotoxicity of isoxyl particles on human macrophages, and the 
efficacy of these particles on intracellular growth of a model mycobacterium, BCG, in these 
phagocytic cells. In the study, THP-1 cells were exposed to a series of concentrations of 
isoxyl in the forms of either microparticles or nanoparticles/molecules. MTT (methylthiazol 
tetrazolium) and LDH (lactose dehydrogenase) assays were utilized to test cytotoxicity of the 
drug. Microparticles and nanoparticles of concentrations up to 100 µg/ml were not toxic to 
macrophages, but nanoparticles seemed to deliver more drug to the cells because they 
reduced MTT more than controls and microparticles. Preliminary studies of the in-vitro 
efficacy were performed by incubating the infected THP-1 cells with mycobacteria. The 
results suggested that different forms of isoxyl seem not have changed in in-vitro efficacy to 
kill tuberculosis bacteria inside the cells. Both isoxyl microparticle suspension and isoxyl in 
1% DMSO showed bactericidal activity at a concentration of 5 µg/ml. In the future, the study 
of in-vitro drug efficacy will be repeated and additional drug concentrations will be tested. 
Also, bronchoalveolar lavage cells (BALs) from guinea pigs will be used to evaluate in-vitro 
cytotoxicity and efficacy of these isoxyl microparticles and nanoparticle/molecule controls 
again. The results will be compared with those obtained from THP-1 cells and for subsequent 
comparison with in-vivo data. Even though isoxyl microparticles might not be different from 
nanoparticles/molecules in terms of in-vitro efficacy, in-vivo studies of both forms of isoxyl 
are necessary in the future. Particles delivered to the lungs can have very different disposition 
in-vivo due to: 1) The hydrophobic environment of the lungs may increase the rate of 
dissolution; 2) there are different components of the lungs, such as lung surfactants, in 
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comparison to cell culture media which may facilitate or prevent phagocytosis; 3) 
heterogeneous macrophages in the lungs can have variable functions; and 4) availability of 
other cells such as epithelial cells may eliminate the drug via other pathways. 
Modern analytical and drug delivery techniques were employed to resurrect the 
prospects of isoxyl, an antitubercular drug, as an effective therapeutic agent. Establishing 
particle manufacturing processes, in-vitro effect, in the absence of cytotoxicity, and 
analytical methods in biological fluids are prerequisites for conducting efficacy experiments 
in infected animal models as a precursor to regulated clinical studies. The methods described 
in this thesis form the basis for future work on the treatment of resistant tuberculosis lung 
infection by isoxyl or other analogs within this class of drugs. 
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